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Seafood is one of the most common food items that cause food allergy. It is 
found that tropomyosin is one of the major seafood allergens in human diet. Despite 
years of investigations, the mechanisms involved in food allergy are poorly 
understood. Numerous studies have been done to investigate the molecular 
mechanisms and characterize the allergen epitopes for the development of novel 
therapies. In this study, purified recombinant protein of the shrimp tropomyosin was 
used to feed BALB/c mice by oral gavage and mouse splenocytes were used for 
epitopes mapping. The goal is to identify the T cell epitopes of tropomyosin 
utilizing the developed mouse model which closely mimics the human hypersensitive 
responses in shrimp allergy. 
Shrimp {Metapenaeus ensis) tropomyosin in the His-tag expression vector 
pQE-30 was available. It was transformed into E.coli for expression of recombinant 
protein. Recombinant tropomyosin was purified by chromatography using 
nickel-nitrilotriacetic acid column. Two groups of three to four-week-old female 
BALB/c mice were fed with 0.1 mg tropomyosin with cholera toxin as the adjuvant 
(experimental groups). In the first group of mice, they were fed weekly with 
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tropomyosin. Another group of mice was fed 12 days apart between the first and 
second feeding and then weekly apart for the other sensitization. Mice fed with PBS, 
His-tag protein and lysozyme were used as control. After four times of sensitization, 
mice were challenged with 1 mg tropomyosin in all groups. Mice which immunized 
with recombinant tropomyosin in the second group developed signs of allergic 
responses. These mice scratched around the snouts, bodies and tails. And the 
snouts of mice swelled. Tropomyosin-specific IgE was intensively induced in this 
group of mice. On the other hand, tropomyosin-specific IgE level induced in the 
first experimental group (feeding weekly) was not much different from that induced in 
control mice. 
Mice in the second experimental group which showed allergic responses were 
sacrificed. The spleens were removed and splenocytes were prepared for T cell 
epitope mapping. Eighteen overlapped synthetic peptides which encoded the full 
length of Metapenaeus ensis tropomyosin was synthesized on an automated peptide 
synthesizer. These synthetic peptides were added into the mouse splenocytes 
separately or in groups to stimulate splenocyte proliferation. Each of the synthetic 
peptide groups contained three different synthetic peptides. Splenocytes stimulated 
with recombinant tropomyosin and phytohemagglutinin were used as positive control 
and ovalbumin as negative control. Tritiated thymidine was added during cell 
incubation and tritiated thymidine incorporation was measured by a p-scintillation 
counter. Proliferation was calculated by the ratio of incorporated radioactivity in the 
presence and absence of testing peptides. When three synthetic peptides, 4，10 or 15, 
were added, splenocytes proliferated actively in vitro. These synthetic peptides 
represented the residues 53-72, 143-162 and 218-237 respectively. Splenocytes were 
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also induced to proliferate when they were stimulated with synthetic peptide groups 
which contained synthetic peptides 4，10 or 15. The splenocytes stimulation with 
synthetic peptides groups 2-4, 8-10 and 15-17 spanning the residues 23-72, 113-162 
and 218-267 showed stronger proliferation of splenocytes. Another five synthetic 
peptides, 2，3，8，14 and 17 representing the residues 23-42，38-57, 113-132, 203-222 
and 248-267，moderately stimulated splenocytes to proliferate. 
It is concluded that oral sensitization of mice with shrimp tropomyosin could 
elicit allergic responses to the immunized food antigen. The developed mouse 
model could be used for future study on seafood allergy. The identification of T cell 
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Allergies are the fifth leading cause of chronic diseases in the United States among 
all ages and the third common chronic disease among children under 18 years old. It is 
estimated that more than 50 million Americans suffer from allergic diseases which 
makes a great economic impact to the country as the costs associated with it are 
extraordinarily high (Huges and Mills 2001). Food allergy remains a leading cause of 
anaphylaxis and it is believed that around 33% of anaphylactic reactions are caused by 
food. Every year, approximately 150 Americans, usually adolescents and young adults, 
die from food-induced anaphylaxis (National Institute of Allergy and Infectious 
Diseases 2005). Food-related anaphylaxis is a growing problem over the world. Among 
various types of food allergens, seafood continues to be the leading cause of food 
hypersensitivity. Shrimp has topped the list of the most consumed seafood product and 
shrimp allergies are most frequently reported (Laurianne and Samuel 2005). Despite 
years of investigation, the underlying mechanisms for food allergy have not clearly 
understood yet. Thus the only effective therapy to food allergy is to avoid contacting 
the allergic foods. 
Tropomyosin has been identified as a major seafood allergen in crustaceans. This 
heat stable, double helix allergen has been identified, sequenced and cloned in the 
shrimp and other shellfish extensively by different research groups. Numerous studies 
were aimed for studying the cross-reactivity of tropomyosin among related food items 
and revealing the immunoglobin E (IgE) binding epitopes of the allergen. Although 
the IgE binding epitopes were intensively investigated, the identification of shared 
and unique IgE binding epitopes in tropomyosin were still not clear. 
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Scientists are working hard for elucidating the immimopathogenesis of food 
allergy, but it is clear that the IgE-mediated immune response involves both B and T 
cells. The allergic symptoms are caused by the cross-linkage of the mast cells bound 
IgE by the allergen peptide which contains the IgE binding epitope. The identification 
of the IgE binding epitope gives useful information for developing IgE binding 
epitope modified allergen. However, the activation of the B cells are triggered by the 
T cells which are activated by the presence of the T cell epitope on the allergen. The 
identification of the T cell epitopes is therefore a critical component of the design and 
implementation of therapies for food allergy. 
Animal models of allergy studies refer to the use of animals to test for the 
allergenicity of particular food items or to mimic the biochemical reactions in human, 
thus allowing us to investigate the physiological basis of allergic and other biochemical 
reactions related to food allergy. The use of animal models for studying food allergy 
including wheat, milk and peanut had been reported by various research groups 
(Buchanan and Frick, 2002; Helm, 2002; Helm and Burks, 2002). But no attempt was 
made to apply tropomyosin in inducing hypersensitivity responses which mimic human 
food allergy responses in animals. Our laboratory was the first one to develop an 
animal model by applying tropomyosin in hypersensitivity responses of which mimic 
human food allergy responses (Tang et a?/.2003). In the present study, synthetic 
peptides spanning the shrimp allergen was produced for identifying the T cell epitopic 
regions on the allergen ultilizing the animal model. 
The goal of this thesis research is to identify the T cell epitopes of Metapenaeus 
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ensis tropomyosin, which will allow future studies on the design of therapeutic 
modalities. The specific objectives of the present study are therefore to (1) 
characterize the developed mouse model of allergic response to shrimp, and (2) 
determine the T cell epitopes of tropomyosin by the mouse model. 
Chapter 2 of this thesis is a literature review on the background information of 
food allergy, mechanism and clinical symptoms of food allergy, basic information on 
the major shellfish allergen tropomyosin, the studies of eptiopes mapping of allergens 
and novel approaches for the treatment of food allergy. Chapter 3 presents the 
studies on the preparation of tropomyosin and sensitization of mice to shrimp allergy. 
T cell epitopes mapping of tropomyosin is described in Chapter 4. Chapter 5 is the 




This chapter reviews the literature on the (1) food allergy and its prevalence; (2) 
mechanism and clinical symptoms of food allergy; (3) tropomyosin as the major 
allergen in shellfish; (4) cross-reactivity and epitope mapping of tropomyosin and (5) 
novel approaches for the treatment of food allergy. 
2.1 Food allergy and its prevalence 
Other than water and air, food is essential for life. It is also a major source of 
pleasure and often reflects a cultural identity. Most individuals have three meals a day 
plus some snacks and consume food with others in social gathering. In westernized 
societies, two to three tons of foods are ingested by each individual in a lifetime. 
Unfortunately, some people had provoked adverse reactions to some food components. 
These abnormal reactions may be due to adverse physiological and immunological 
reactions (Sampson 1999). 
Hippocrates was the first to describe the adverse reactions to food over 2000 
years ago, but there have been no further investigations until recently. In the first and 
second centuries, some Greek scholars recorded adverse reactions to cow's milk 
(Cohen and Saavedra-Delgado 1989). The first anaphylactic reaction to egg and fish 
was identified by Marcello Donati in the 16th century and Philipp Sachs in the 17th 
century respectively (Avenberg and Harper 1980). The first skin test was performed 
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by Charles Blakely in. 1869 for investigating his own hay fever caused by pollen. He 
applied pollen through a small break in his skin, a hive like response was observed 
after 20 minutes. In 1950，Loveless first used blinded, placebo-controlled food 
challenges (DBPCFCs) to establish the diagnosis of food allergy (Loveless 1950). The 
early study of allergy was conducted by Kimishige and Teruko Ishizaka who 
discovered in 1967 that IgE class antibodies are the principal mediator in the allergic 
reaction. They found that allergic individuals produced IgE antibodies after repeated 
exposure to an allergen. Afterwards, IgE antibodies became the major area for 
studying allergy. 
It is estimated that more than 50 million Americans suffer from allergic diseases 
and more than 54.6% of all United States citizens test positive to one or more 
allergens. Allergies are the fifth leading cause of chronic disease in the United States 
among all ages and the third common chronic disease among children under 18 years 
old. Allergic diseases have a great economic impact to the country as the associated 
costs are extraordinarily high. An estimate is that $7.9 billion per year, of which $4.5 
billion was spent on direct care and $3.4 billion on indirect costs, related primarily to 
lost work productivity (AAAAI 2007). Food allergy remains a leading cause of 
anaphylaxis and it is believed that around 33% of anaphylactic reactions are caused 
by food (Huges and Mills 2001). Food allergy affects about 6% of infants and 3 to 4% 
of adults (Sampson 2003，Gideon 2004, Scott and Sampson 2006). Every year, 
approximately 150 Americans, usually adolescents and young adults, die from 
food-induced anaphylaxis (National Institute of Allergy and Infectious Diseases 2005). 
In the United States, eight foods account for 90% of all reactions; they are milk, eggs, 
peanuts, tree nuts, wheat, soy, fish and shellfish. Food allergy is not only reported in 
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United States, it also affects some of the European and Asian countries. Surveys from 
the United Kingdom indicate that 1.4% to 1.8% of adults experience adverse food 
reactions. Another study in Netherlands reports that about 2% of the adult Dutch 
population is affected by adverse food reactions (Sampson 1999). A review conducted 
in a clinical immunology/allergy centre in Singapore shows that 44.8% of adults with 
anaphylaxis presented to this center is caused by food. The occurrence of food allergy 
appears to have geographical distribution. For instance, seafood allergy is more 
common in countries around the Mediterranean than western Europe (Hughes and 
Mills 2001). It also reflects the regional dietary habits; rice and soya allergies are 
more prevalent in the Far East than western countries. Food allergy has been 
recognized as a worldwide problem in westernized nations and the awareness from 
the public is increasing. 
2.2 Mechanism and clinical symptoms of food allergy 
Although there are enormous diversity of the human diets, only relatively few 
foods are responsible for most food allergies. Food allergy can be divided into two 
types: Sensitization to food allergens in the gastrointestinal tract after food ingestion 
is considered as Class 1 food allergy in which the major allergens are water-soluble 
glycoproteins with 1 0 - 7 0 kDa and generally stable to treatments with heat, acid and 
proteases or digestion. Class 2 food allergy is identified as sensitization to allergens 
during allergen exposure in respiratory tract after inhalation of an airborne allergen 
that cross-reacts with a specific food. Most of the Class 2 allergens are plant-derived 
proteins that are highly heat labile and difficult to isolate (Breiteneder and Ebner 2000, 
Chehade and Mayer 2005). In children, 85% of documented food allergies are caused 
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by cow milk, egg, peanut, soy, wheat and fish, whereas peanuts, tree nuts, fish and 
shellfish are the major causes in adults'. 
Since the gastrointestinal tract is the first to confront the food allergens, a variety 
of gastrointestinal disorders may develop. Food allergy might be IgE mediated, partial 
IgE mediated or non-IgE mediated. However, IgE mediated (Type 1) hypersensitivity 
reactions account for the majority of well-documented food allergy reactions. A 
variety of gastrointestinal, cutaneous, respiratory and generalized symptoms and 
syndromes have been associated with IgE mediated food allergy. The development of 
an IgE mediated response to an allergen is the result of a series of molecular and 
cellular interactions involving antigen-presenting cells (APCs)，T cells and B cells 
(Vercelli and Geha 1991). 
The complex structure of the gastrointestinal mucosal barrier provides a giant 
surface area for processing and absorbing ingested food and discharging waste 
products (Mayer 2003). The gut-associated lymphoid tissue is capable of 
discriminating among harmless foreign proteins or commensal organisms and 
dangerous pathogens. Yet abrogation of the barrier or developmental immaturity 
might promote food allergy. Studies show that the prevalence of food allergy is 
highest in infants because of the developmental immaturity of various components of 
the gut and immune system which reduces the efficiency of their mucosal barrier 
(Bock 1987，Weaver et al 1987). Even in the mature gut, about 2% of ingested food 
are absorbed and transported throughout the body in an "immunologically" intact 
form (Husby et al 1987). Although intact food antigens penetrate the gastrointestinal 
tract routinely, most individuals acquire tolerance. Food antigens are typically poor 
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immunogens and induce a state of unresponsiveness known as oral tolerance. Thus, 
most individuals do not have any clinical symptoms. Recent studies suggest that 
various APCs, especially intestinal epithelial cells and various dendritic cells，and 
regulatory T cells play a central role in oral tolerance (Mowat 2003, Chehade and 
Mayer 2005). Intestinal epithelial cells respond to oral tolerance by acting as 
nonprofessional antigen-presenting cells (Mayer 2000)，processing and presenting 
antigens to T cells on an MHC class II complex without a second signal (Chehade and 
Mayer 2005). The expression of IL-10 and IL-4 in dendritic cells residing within the 
lamina propria and noninflammatory environment of Peyer's patches also favor the 
generation of tolerance (Frossard et al 2004). It is believed that the unresponsiveness 
of T cells to ingested food proteins is the result of T-cell anergy or induction of 
regulatory T cells. The tolerance induction is also affected by the properties of 
antigens, dose and frequency of exposure. High-dose tolerance involves deletion of 
effector T cells, whereas activation of regulatory T cells with suppressor functions is 
mediated by low-dose tolerance (Chehade and Mayer 2005). Other than the cells, gut 
flora which establishes in the first 24 hours after birth also plays a significant role in 
oral tolerance induction. The establishment of gut flora depends on maternal flora, 
genetics and the local environment. 
When oral tolerance fails to develop normally or breaks down in genetically 
predisposed people, food hypersensitivity will develop. IgE mediated reactions 
develop under the following conditions: (1) food specific IgE antibodies residing on 
mast cells and (2) basophils bind to circulating ingested food allergens. The cells are 
activated and release a number of potent cytokines. The interactions and relationships 
between a food allergen, APCs, T cell and B cells are illustrated in Figure 2.1. After 
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Fig. 2.1 IgE-mediated seafood allei^ mechanism. Food allergen crossed through 
the mucosal membrane barriers is processed and presented on the MHC 
class II molecule by the antigen presenting cells (APC). T helper cell (Th) 
recognizes the processed allergen peptide and is activated. B cell is 
stimulated by the cytokines released by the activated Th cell and produces 
allergen-specific IgE antibodies which associate with mast cell. Secondary 
exposure of the food allergen cross-links the mast cell-bound IgE 
antibodies and results in mast cell degranulation. The performed or newly 
formed mediators (e.g. histamine) cause a series of clinical effects of 
allergic reactions. 
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digestion in the stomach, the food allergens are broken into small peptide fragments 
(10 - 20 amino acids long). APCs present the small peptide fragments in conjunction 
with MHC class II molecules to T cells. This presentation is MHC restricted because 
the T cell receptors can only recognize a corresponding antigen when it is presented 
on an APC together with the MHC (Elson 1985, Roitte et al 1985). The binding of 
the complementary T cell receptor to the antigen-MHC complex leads to T cell 
proliferation, cytokine production and the generation of signal which promotes an IgE 
response (Vercelli 1995a, b). The exposure of the antigen to T cells activates the 
development of T helper 2 (Th2) cells specific for the antigen and promotes the 
production of IgE antibodies specific for the antigen. Thl and Th2 cells are two 
polarized forms of the highly heterogenous CD4+ Th cell-mediated immune response. 
It is suggested that they are developed from the same naive T helper cell under the 
influence of both environmental and genetic factors acting at the level of antigen 
presentation (Abbas et al 1996, Romagnani 2000a). Thl cells are characterized by 
the prevalent production of IL-2, IFN-y and TNF-p. Alternatively, Th2 cells are 
characterized by the prevalent production of IL-4，IL-5, IL-10 and IL-13. It is found 
that these kinds of cytokines increase in abundance in allergic individuals (Umetsu 
and DeKruyff 1997). Each of these cytokines plays different roles in the allergic 
inflammatory response but all are important. IL-4 and IL-13 enhance the induction of 
IgE synthesis in B cells, growth of mast cells, recruitment of lymphocytes, mast cells 
and basophils to sites of inflammation. IL-5 enhances the growth differentiation of 
eosinophils and B cells. The growth differentiation of mast cells and inhibition of 
IFN-y production are enhanced by IL-10. Allergen specific Th2 cells play an 
important role in induction and maintenance of allergy and this is demonstrated by 
their presence in peripheral blood and the nasal mucosa of patients with rhinitis (Del 
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Prete et al. 1993), in skin lesions of patients with atopic dermatitis (Parronchi et al 
1991) and in the bronchial alveolar lavage fluid of patients with asthma (Bodey et al. 
1999). 
The differentiation of the naive Th cells into Th2 cells is favored by the early 
presence of IL-4. While the source of IL-4 produced at the beginning of the immune 
response is not fully known, the early interaction of IL-4 with its receptor on the 
surface of the naive Th cells results in the activation of the transcription of signal 
transducer and activator of transcription 6 (STAT6). Another transcription factor, 
GATA-3, is more important for Th2 differentiation because it inhibits the production 
of IFN-y (Thl cytokine), increases the transactivation of the IL-4 promoter and also 
directly regulates IL-5 and IL-13 expression. Thus GATA-3 not only plays a global 
role in upregulating Th2 cytokines but also concomitantly inhibits Thl development. 
These indicate the major role of the transcription factors in determining the Th2 
response (Rengarajan et al 2000). 
The IgE antibodies produced bind to mast cells or basophils until the second 
exposure of the allergen. The mast cell IgE and IgE receptor network play an 
important role in regulating allergic reactions (Ochi et al. 2000, Pawankar 2001). IgE 
antibodies are bound to mast cells, basophils and eosinophils via a high affinity Fc 
receptor specific for 8 heavy chains (FceRI). Each FceRI molecule is composed of one 
a chain that mediates IgE binding and one p and two y chains that are responsible for 
signaling. The amino terminal extracellular portion of the FcsRI a chain consists of 
two Ig-like domains and constitutes the IgE binding site. In non-allergic individuals, 
the mast cell's associated IgE are highly heterologous in antigen specificity. In 
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contrast, a large proportion of the IgE bound to mast cells is antigen specific in 
allergic patients. Thus, cross-linkage of IgE after allergen exposure would occur more 
likely in an allergic individual than in non-allergic individuals. 
If re-exposure of specific allergens occurs, the mast cells bounded IgE would be 
cross-linked by the allergens and trigger a series of immunological responses. The 
degranulation of the mast cells results in the release of preformed and newly formed 
mediators. The effector functions of mast cells are mediated by these soluble 
molecules released upon activation. The key mediators include: (a) histamines; (b) 
granule proteins such as tryptase, chymase, carboxypeptidase A, cathepsin G and 
proteoglycans such as heparin (Saarinen et al 2001a); (c) lipid mediators such as 
prostaglandin D2 and leukotrienes that have a variety of effects on blood vessels, 
bronchial smooth muscle and leukocytes; and (d) cytokines including TNF, IL-1, IL-4, 
IL-5, IL-6, IL-13, MlP-la, MIP-ip (Royer et al 2001, Saarinen et al 2001b) and a 
potent Th2 response inducer IL-25 (Ikeda et al 2003). FceRI is not only expressed on 
mast cells but also on basophils and eosinophils. The ability of eosinophils to release 
granules is enhanced by IL-5 (Togawa et al 2001). Activated eosinophils produce and 
release lipid mediators such as PAF, prostaglandins and leukotrienes (Falcone et al. 
2000, Kawakami and Galli 2002, Piliponsky et al 2002, Prussin and Metcalfe 2003) 
in a similar fashion as mast cells and basophils do. 
Recent studies have suggested the presence of various types of T cells with 
regulatory activity. This heterogeneous family of Treg cells, including TR cells, 
CD4+CD25+ T cells and Th3 cells, is able to suppress the effector immune response 
(Akbari et al 2003，Blucstone and Abbas 2003). Suppression might be mediated by 
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cell-cell contact, as well as through the production of IL-10, TGF-P or both. It is 
found that IL-10 has a number of antiallergic properties (Bellinghausen et al 2001). 
In mouse, IL-10 has been associated with suppression of schistosomal egg-induced 
delayed-type hypersensitivity (Flores-Villanueva et al. 1996). In human T cells, IL-10 
suppresses production of proallergic cytokines, such as IL-5 (Francis et al 2003), and 
is able to induce a state of antigen-specific hyporesponsiveness or anergy (Groux et al 
1997). Although it is generally agreed that allergy is caused by the development of 
allergen-specific Th2 cells in allergic individuals, this is a much simplified picture. It 
is suggested that Treg cells might play a critical role in maintaining immune 
homeostasis in vivo. In additional to Treg cells, resent findings suggest that the net 
effect of antigen dose and the state of maturation of the dendritic cells, together with 
the stimulation of the dendritic cells by pathogen-associated molecular patterns, can 
influence the development of a Thl or Th2 response (Eiscnbarth et al. 2002，Boonstra 
et al 2003). However, the exact mechanism of the Thl/Th2 paradigm is not fully 
understood and clear evidence suggests that it is under the influence of both 
environmental and genetic factors at the level of antigen presentation (Romagnani 
2004). 
The reactions to allergens can be manifested by various ways, depending on the 
route of exposure. The gastrointestinal tract initially comes into contact with the food 
after ingestion, and some of the localized and generalized gastrointestinal symptoms 
are frequently observed in hypersensitive individuals. In man, acute gastrointestinal 
signs and symptoms often start with oedema and pruritus of lips, oral mucosal and 
pharynx, followed by abdominal pain, vomiting, nausea and diarrhea which may be 
haemorrhagic (Bade and Wright 1976, Atkins and Metcalfe 1984, Businco et al. 1984). 
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These reactions take place minutes to hours after ingestion of the offending allergen. 
Repeated ingestion of allergenic foods may lead to poor appetite, intermittent 
abdominal pain and malabsoption which result in weight loss. Oral allergy syndrome 
is considered a form of contact urticaria that rarely involves other target organs but is 
confined almost in oropharynx. The symptoms include rapid onset of pruritus and 
angioedema of the lips, tongue, palate and throat (Burks 2002). Aside from 
IgE-mediated reactions, food allergies may cause other forms of gastrointestinal 
disorders. Allergic eosinophilic gastroenterocolitis (AEG) and allergic eosinophilic 
esophagitis (AEE) are characterized by the infiltration of the esophagus, stomach 
and/or intestinal walls with eosinophils, absence of vasculitis and peripheral 
eosinophils (Waldmann et al 1967). Symptoms include gastroesophageal reflux, 
vomiting, abdominal pain, failure to thrive, low serum albumin, blood vomiting and 
intestinal obstruction (Snyder et al 1987). Respiratory reactions and dermatological 
reactions are also frequently found in patients with food allergies. Respiratory 
symptoms include sneezing, rhinorrhea, nasal obstruction, wheezing, cough and 
ocular signs (Waring et al, 1985, Daul et al. 1987). Airway hyperreactivity and 
worsening of asthma can also be induced in the absence of marked bronchospasm 
after the ingestion of small amounts of food allergens in sensitized subjects (James et 
al 1994). Recently, it is found that food allergy is a major risk factor for severe 
life-threatening asthma (James et al. 1996). Inhalation of vapors or steam containing 
proteins generated by cooking the seafood can induce asthmatic reactions and even 
anaphylaxis (Crespo et al. 1995a, Roberts et al 2003). Food-induced contact 
dermatitis is seen frequently among food handlers, especially those handling raw fish, 
shellfish, meats and eggs (Judd 1994). 
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An unusual form of anaphylaxis, food-associated exercise-induced anaphylaxis, 
is found. It occurs only when patients exercise within 2-4 hours of ingesting a food 
item which they are allergic to. However, in the absence of exercise the patients can 
ingest the food without any apparent reaction (Kidd et al 1983，Dohi et al. 1991， 
Horan and Sheffer 1991). The incidence of food-associated exercise anaphylaxis 
appears to be increasing, possibly because of the increased popularity of exercising. 
The exact mechanism involved in this disorder is unknown, but several foods have 
been found to be implicated, including wheat, shellfish, fruit, milk, celery and fish. 
2.3 Tropomyosin as the major allergen in shellfish 
Food-related anaphylaxis is a growing problem over the world and is now 
estimated to be the single most frequent cause of anaphylaxis treated in emergency 
departments (Bock et al 2001). Among various types of food allergens, seafood 
continues to be the leading cause of food hypersensitivity, including fatal anaphylaxis. 
A survey showed that 66.7% of food-allergic patients presented to the clinical center 
in Singapore were caused by seafood (Thong et al 2005). Seafood allergy is a 
worldwide problem and the prevalence varies with country. It is estimated that about 
6.8% (Crespo et al, 1995b) and 4.4% (Pumphrey and Stanworth 1996) of children are 
allergic to seafood in Spain and England respectively. Approximately 12 million 
Americans are suffering from food allergy with 6.9 million allergic to seafood. A 
well-designed, national wide and cross-sectional random telephone survey (Sicherer et 
al, 2004) found that seafood allergy is reported by 2.3% of the general US population, 
i.e. approximately 6.6 million Americans, where 2.0% were allergic to shellfish and 
0.2% was to both fish and shellfish. 
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Seafood consumption is increasing in the modem diet because of the continued 
awareness about dietary fat and cholesterol and the more efficient distribution of 
seafood products. In the United States, seafood is an important part of the diet and 
economy. The Commerce Department's National Oceanic and Atmospheric 
Administration (2004) announced that world trade in seafood is estimated at US$100 
billion in 1999. The United States is the third largest seafood consumer in the world 
and nearly US$27 billion is spent on seafood each year (Lauriaime and Samuel 2005), 
In 2006，16.5 pounds of seafood was consumed per capita and the total seafood 
consumption was 4.9 billion pounds. Among the seafood, shrimp topped the list of the 
most consumed seafood product since 2001. Shrimp consumption increased 10% 
from 2000 to 3.4 pounds per capita in 2001 and continuously rose to 4.4 pounds in 
2006 (National Oceanic and Atmospheric Administration 2006). 
The identification of seafood allergens is important for elucidating the seafood 
allergic mechanisms. The early study on seafood allergy was conducted by Elsayed 
and Aas (1970) who identified Gad c 7 as the major allergen in codfish (Gadus 
callarias). Gad c 1 belongs to the parvalbumins, a group of muscle calcium-chelating 
proteins in vertebrates, that control the concentration of calcium in muscles (Aas 1969, 
Aas and Elsayed 1969, Closset and Gerday 1971, Demaille et al 1974), Gad c 1 
contains 113 amino acids and 1 glucose molecule, with a molecular mass of 12,328 
kD (Elsayed and Bennich 1975) and an isoelectric point of 4.75 (Elsayed and Aas 
1970). The white muscle parvalbumin was also found to be a major allergen in the 
Atlantic salmon (Salmo salar, Sal s 1) by Lindstrom et al. (1996). Two distinct cDNA 
clones representing two different parvalbumin genes were obtained later and the 
deduced amino acid sequences of both clones were identified to belong to the 
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/5 -lineage of parvalbumins. This study represents the first molecular cloning study of 
a fish allergen and the study was further confirmed by Van Do et al (1999). 
Parvalbimun also represents a cross-reactive fish allergen among different fish species 
including cod, salmon, mackerel (Shiomi et al 1998) and carp (Bugajska-Schretter et 
al. 1999，Swoboda et al. 2002). Although parvalbumin has been identified as the 
major fish allergen, other species-specific fish allergens have been reported in 
swordfish, surimi, tuna, trout, pollock and native codfish (Mata et al. 1994，Kelso et 
al 1996, Galland et al 1998). 
The molecular identification of shellfish allergens began in 1980s. Hoffman et al 
(1981) were the first to purify two allergens from raw and cooked shrimp respectively, 
termed antigen I and antigen II. Antigen I is a dimmer of two polypeptide chains and 
has a molecular weight of 21 kDa. Antigen II is a polyglycoprotein with a 
carbohydrate composition of approximately 4.0%. It has a molecular weight of 38 
kDa with an isoelectric point of 4.5. Nagpal et al (1989) isolated and characterized a 
heat stable allergen (Sa-II) from the shrimp Penaeus indicus. Another similar shrimp 
allergen, a 36 kDa protein {Pen a 1) was isolated from Penaeus aztecus (Daul et al. 
1994). Independently, Shanti et al (1993) reported high homology in the amino acid 
sequence between allergen Sa-II (also referred as Pen i 1) and the muscle protein 
tropomyosin of the fruit fly Drosophila melanogaster. The cloning of the major 
shrimp allergen was firstly reported by Leung et al (1994). They identified the 
allergen from Metapenaeus ensis by screening a cDNA library of shrimp muscle with 
sera from patients with shellfish allergy. This allergen, called Met e 1, has an open 
reading frame of 281 amino acids, coding for a 34 kDa protein. They also found that 
the amino acid composition and the deduced amino acid sequence of antigen II’ Sa-II, 
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Pen a 1 and Met e I aiQ highly homologous to the Drosophila melanogaster 
tropomyosin. This suggests that all investigators isolated a similar or identical 
allergen from different shrimp species, and this shrimp allergen represents the muscle 
protein tropomyosin. Tropomyosin is a highly conserved protein bearing multiple 
isoforms in muscle and non-muscle cells of both invertebrates and vertebrates. 
Tropomyosin is responsible for contractile activities in muscle cells and cell 
morphology and motility regulation in nonmuscle cells. In association with the 
troponin complex, tropomyosin functions in the regulation of calcium-sensitive 
interaction of actin and myosin (Reese et al 1999b). Tropomyosin is composed of 
two parallel polypeptide chains which wind around each other forming a coiled-coil 
formation (Smile 1979). 
In additional to shrimp, tropomyosin has been identified as the major allergen in 
various crustacean and mollusk species. An IgE reactive clone, named as Cha f 1, was 
yielded from a cDNA library from the common crab Charybdis feriatus. This clone 
showed an open reading frame of 264 amino acids and was found to be tropomyosin 
by amino acids comparison. The IgE reactivity to Cha f 1 was totally inhibited when 
the sera were preincubated with recombinant Met e 1 (Leung et al 1998a). Leung et 
al (1998b) also constructed a cDNA library from the spiny lobster Panulirus 
stimpsoni and screened for IgE reactive clone with sera from crustacean allergic 
patients. The expressed 60 kDa recombinant protein was recognized by serum IgE of 
crustacean allergic subjects and showed 98.2% similarity in amino acid sequence 
between Pan s 1 and Met e 1. The tropomyosin gene has been cloned in the American 
lobster Homarus americanus (Mykles et al 1998)，designated as Horn a 1. Both 
recombinant Pan s 1 and Horn a 1 proteins inhibited the IgE reactivity of sera from 
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allergic patients against Met e 1. When crustacean allergic patients sera were 
preincubated with recombinant Met e 1, Pan s 1 oi Horn a 1, the IgE reactivity to 
crude lobster extracts were lost. Thus, it was believed that these recombinant 
tropomyosin share similar epitopes (Leung et al 1994，1998a，1998b). 
Leung et al (1996) showed that sera from patients with shrimp allergies react 
specifically to a 38 kDa protein in a wide variety of mollusks from class Gastropoda 
(abalone and limpet), Bivalvia (scallop, mussle and oyster) and Cephalopoda (squid, 
octopus and cuttlefish). Preabsorption of shrimp allergic subjects' sera with 
recombinant shrimp tropomyosin Met e 1 could inhibit the IgE-binding reactivity to 
mollusk extract, suggesting that tropomyosin was a common allergen among 
crustaceans and mollusks. Among gastropods, Lopata et al (1997) demonstrated that 
there were two major allergens with molecular weights of 38 kDa and 49 kDa in 
abalone (Haliotis midae). While the 38 kDa protein was believed to be tropomyosin, 
the identity of the 49 kDa protein, coined Hal m 1, was not resolved. A 35 kDa 
allergen, named Tur c 1, of turban shell Turbo cornutus was identified (Ishikawa et al. 
1998a). The amino acid composition and partial amino acid sequences implied that it 
was tropomyosin. Asturias et al (2002) isolated and cloned tropomyosin {Hel as 1) 
from the brown garden snail, Helix aspersa. They found that this 36 kDa protein 
shared 84% of its amino acid sequence identity with abalone {Haliotis diversicolor), 
70% with mussel {Mytilus edulis) and 72% with scallop (Chlamys nobilis) 
tropomyosins. Ishikawa et al (1997) purified two similar allergens, Cm g 1 and Cra g 
2, from the Pacific oyster Crassostera gigas. Later on, Leung and Chu (2001) 
indicated that Cra g 1 and 2 represented the same or similar isoforms of oyster 
tropomyosins. They had also amplified the cDNA of tropomyosin from abalone 
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{Haliotis diversicolor), scallop {Chlamys nobilis) and mussel {Perna viridis) and 
demonstrated their IgE reactivity (Chu et al 2000). Comparison of the amino acid 
sequences of tropomyosin of these three mollusks to those mollusks available from 
the GeneBank database showed that they were highly conserved. Tropomyosin of 
another bivalve species, the sea scallop Placopecten magellanicus, was cloned and 
expressed (Patwary et al 1999). This 30 kDa protein, encoded of 284 amino acids, 
shared 70% identity to tropomyosins from other mollusks. In cephalopods, a 38 kDa 
heat-stable allergen {Tod p 1) from the squid Todarodes paciflcus was isolated. The 
peptide sequence of this allergen showed high homology to the snail tropomyosin 
(Miyazawa et al 1996). In additional to turban shell and oyster tropomyosin, 
Ishikawa et al, (2001) identified tropomyosin in the octopus Octopus vugaris from its 
muscle, named Oct v 1. Cross reactivity between Oct v 1 and Tur c 1 was suggested 
by competitive ELISA inhibition experiments. 
Besides tropomyosin, a number of multiple allergens were found among 
crustaceans (Lehrer et al 1985, Lehrer 1986). A novel allergen, named as Pen m 2� 
was recently identified by Yu et al (2003) from the shrimp Penaeus monodon by 
immimoblotting using sera from patients with shrimp allergy. Pen m 2 was found to 
be 39.9 kDa, encoding a 356 amino acid protein. This protein showed similarity to 
arginine kinase of crustaceans and exhibited arginine kinase function. The reactivity 
of purified arginine kinase from shrimp, lobster, crawfish and crab with oiiXi-Pen m 2 
antibody reactivity and sera from shrimp-allergic patients indicates arginine kinase as 
a common allergen among crustaceans. 
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2.4 Cross reactivity and epitope mapping of tropomyosin 
Since tropomyosin was found to be the major allergen in various shellfish, it is 
believed that the same hypersensitive responses would be elicited when allergic 
patients consume any shellfish species. The trigger of the same responses by related 
food items is called cross-reactivity. Cross-reactivity among shellfish has been widely 
demonstrated in several studies. Some shrimp hypersensitivity individuals had 
positive skin and RAST reactions to crab, crawfish and lobster even though they have 
not been exposed to non shrimp species (Waring et al 1985). Recently, immunoblot 
studies with sera from shrimp allergic subjects or with shrimp Pen a /-specific 
monoclonal antibodies against Pen a 1 exhibited similar reactivity patterns in other 
crustacean species, including crab, crawfish and lobster (Daul et al. 1993). The first 
evidence of cross reactivity at the molecular level was demonstrated by Leung et al 
(1996，1998a, 1998b) who showed that preincubation of sera from shellfish-allergic 
patients with recombinant proteins Met e 1, Pan s 1 or Horn a 1 would lose their IgE 
reactivity to crude crustacean extracts. These studies explained why shrimp-allergic 
patients were hypersensitive to other crustaceans even in the absence of prior 
exposure. Cross-reactivity between crustaceans and other invertebrates was widely 
reported by different research groups. Immunoblotting of sera from shrimp-allergic 
subjects showed IgE reactivity to protein extracts from Gastropoda, Bivalvia and 
Cephalopoda. Moreover, the same sera lost all IgE binding to the protein extracts after 
preabsorbed with recombinant shrimp tropomyosin. Cross-reactivity among 
arthropods was demonstrated in the same study where sera from subjects with 
crustacean allergy showed IgE reactivities against insects (Leung et al 1996). In 
addition to the above study, cross-reactivity between crustaceans and insects or 
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Arachnida had also been widely studied (Crespo et al 1995c, Eriksson et al. 1989， 
O'Neil et al 1985，Witteman et al 1994). Although invertebrate tropomyosin was 
found to be the major cross-reactive allergen, vertebrate tropomyosin was 
non-allergenic. Subjects allergic to vertebrate meat showed IgE binding to a number 
of commercial beef, pork，rabbit and chicken proteins but not to tropomyosin. (Restani 
et al 1997). Parvalbumin, a fish muscles protein, is identified as the major allergen 
responsible for cross-reactivity among distinct species of fish and amphibians. These 
indicated that tropomyosin is not an important vertebrate meat allergen. Individual 
study performed by Leung et al (1996) and Reese et al, (1996a) showed that Pen a 
/-specific IgE antibodies did not cross-react with any of the mammalian tropomyosins 
or their fragments by dot blot and imrrmnoblot analysis. 
The presence of common epitopes on the allergens' or similar epitopes 
conformation which the antibody would bind with similar affinity is the possible 
reason of cross-reactivity. Since epitopes on the allergens play an important role in 
determining allergenicity, epitopes characterization in tropomyosin is needed for 
further understanding the allergenic mechanism and developing therapy. Shanti et al 
(1993) first identified two IgE-binding epitopes in the allergen Pen i 1 by analyzing 
the IgE antibody reactivities of shrimp allergic patients and control subjects to nine 
tryptic digested fragments of Pen i 1. Two of the nine digested fragments individually 
blocked up to 50% of the binding of allergen-specific IgE to tropomyosin in the 
competitive ELISA inhibition experiment. These peptides (digested fragments), 
consisting of the amino residues 153-161 (peptide 6) and 50-66 (peptide 9)，were 
identified by dot-blot using sera from shrimp allergic patients but not from control 
subjects. Comparison of these two regions in the corresponding regions in 
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tropomyosins of insects and vertebrates revealed that the residues 50-66 (peptide 6) 
had higher degree of identity between shrimp and insect than to vertebrates, while 
residues 153-161 were similar between shrimp and vertebrates, except the first two 
residues. The lack of allergenicity in vertebrates suggested that residue Phe-153 and 
Leu-154 were critically involved in IgE binding (Daul et al 1994，Leung et al 1994， 
Shanti et al 1993). 
In order to characterize IgE epitopes of Pen a 1, Reese et al. (1996b, 1997) 
screened a unidirectional expression cDNA library from P. aztecus tail muscle with a 
Pen a i-specific monoclonal antibody and identified four clones. Recombinant 
proteins from the clones were recognized by sera from shrimp-allergic individuals in 
immunoblot analysis. A peptide library was then constructed by using one of the 
clones. The library expressed 10-30 amino acid peptides of Pen a 1 and was screened 
with sera from allergic patients. Four IgE reactive peptides ranged from 13 to 21 
amino acid long, namely peptide E2 (residues 167-179)，E3 (136-148)，E4 (262-282) 
and E6 (157-169)，were identified. All peptides were identical among all allergenic 
crustacean tropomyosins and located in the center and C terminus of the molecule 
(Reese et al 1999a). Peptide E6 was 92% identical to various vertebrate tropomyosins. 
However, other IgE binding epitopes might not be identified as a result of loss during 
fragmentation in the library construction process. 
In a recent study, a more systematic analysis of IgE binding epitopes of Pen a 1 
was done by Ayuso et al (2002a). 46 overlapping peptides of 15 amino acids long and 
with six overlapped amino acids, spanning the entire Pen a 1 tropomyosin were 
synthesized and tested for IgE binding with sera from 18 shrimp-allergic subjects. The 
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reactivity pattern for each individual varied and the number of peptides bound by an 
individual serum ranged from one to 15 (mean = 8). However, based on the frequency 
and intensity of the IgE reactivity, five major IgE binding regions were identified: 
region 1 (43-57), region 2 (85-105)，region 3 (133-153), region 4 (187-201) and 
region 5 (247-284). These epitope regions were positioned at regular intervals of 
approximately 42 amino acids apart, suggesting some relations with the coiled-coil 
structure of the tropomyosin molecule since the major IgE-binding regions were 
spaced approximately every six heptads. 
Since the epitope is the shortest peptide with maximal IgE-binding ability, Ayuso 
et al (2002b) further studied the five major epitope regions and identified eight 
epitopes. The results were based on the reactivity of synthetic peptides with different 
amino acid substitutions present in the lobster {Horn a 1 and Pan s 1\ cockroach {Per 
a 7) and house dust mites (Der f 10 and Der p 10) to sera from shrimp-allergic 
subjects. The eight cross-reactive epitopes were: the first epitope (43-55) in region 1， 
the second epitope (97-101) in region 2, the third (3a: 137-141) and fourth (3b: 
144-151) epitopes in region 3, the fifth (187-197) epitope in region 4, and the last 
three epitopes (5a: 249-259; 5b: 266-273; 5c: 273-281) in region 5. They also showed 
that even homologous regions of other arthropod tropomyosins that differ in one or 
more amino acids from the sequence of Pen a 1 epitopes could still be recognized by 
sera of shrimp-allergic subjects. The IgE reactivity of shrimp-allergic sera to peptides 
with identical amino acid sequence of the other invertebrates explained the basis of 
cross reactivity between these species. Based on the degree of identity between 
different taxa, the eight epitopes could be classified as three types. Epitope 5a was 
classified as the first type, which was the common epitope among crustaceans, insects, 
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mites and mollusks, since this region was almost identical among all species. The 
second type was those epitopes with amino acid residues that were highly conserved 
in arthropods but were different from mollusks, including epitopes 2, 3a, 3b and 4. 
They might represent epitopes that were common to arthropods, but distinct from 
mollusks. In the third type, amino acid residues of the epitopes were similar within 
each taxon but varied considerably between taxa. Epitopes 1，5b and 5c which were 
specific to crustaceans only were classified as this type. In a previous study, Leung 
and Chu (2001) showed that pre-absorption of sera from oyster-allergic subjects with 
recombinant shrimp allergens was able to remove most but not all of the IgE 
reactivity to either recombinant oyster allergen or extract. The above classification of 
epitopes might account for this finding and demonstrate the presence of both shared 
and unique epitopes in the tropomyosin allergens from different taxonomic groups. 
Epitopes of mollusk tropomyosins were reported by Ishikawa et al, (1998a, 
1998b，2001). Oyster tropomyosin, Cra g 1，was digested by lysylendopeptidase and 
generated 21 peptides (Ishikawa et al 1998b). The inhibitory capability of each 
peptide to IgE antibodies from crustacean- and mollusk-allergic subjects to Cra g 1 
were assessed by ELISA inhibition. One of the peptides, K21 (residues 92-105) 
showed maximal inhibition and was proposed to be the IgE-binding epitope of oyster 
tropomyosin. IgE-binding epitope of turban shell tropomyosin, Tur c 1, was 
determined by ELISA inhibition as above (Ishikawa et al 1998a). Four of the 18 
tryptic digested peptides showed substantial inhibition in the inhibition ELISA. 
Sequencing of these peptides showed that the IgE-binding region was located at the C 
terminal (residues 256-284). Yet the IgE-binding epitopes in Crag 1 and Tur c 1 were 
different. In another study (Ishikawa et al 2001), three IgE-binding epitopes were 
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identified in the allergen Oct v 1 from the octopus, two were positioned at the central 
region (residues 77-112 and 148-160) and one at C terminal region (residues 269-281). 
Peptide 77-112 which was the most reactive site for IgE binding included the whole 
segment corresponding to the IgE-binding epitope (residues 92-105) of Cra g 1 and 
overlapped with epitope 2 (residues 87-101) in Pen aim the shrimp. A previous 
study (Ishikawa et al 1999) showed that both N terminal (residues 92-96) and C 
terminal (residues 103-105) regions in the IgE-binding epitope of Cra g I were more 
essential than the middle region (residues 97-102). They also showed that there were 
two alternations at positions 98 and 99 in Oct v 1. However, the highly conserved 
amino acid residues at positions 92-96 and 103-105 supported the IgE binding ability 
of Oct V 1. But the same region in Tur c 1 was not considered as an epitope, and this 
might be related to the replacement of the amino acid residue at position 93. Residues 
269-281 were nested within the epitope of Tur c 1 and partially overlapped with the 
epitopes 5b and 5c in Pen a 1. Although this sequence was highly conserved among 
mollusks, it was not recognized as an epitope in Cra g 1. Ishikawa et al. (1999) 
suggested that it might be due to the differences in sera used. Clearly more intense 
studies are necessary to clarify the shared and unique epitopes in tropomyosin 
allergens. 
The development of an IgE-mediated immune response requires a series of 
interactions involving APC and T and B cells. The activation of B cells is stimulated 
by the activated T cells. As discussed in section 2.2，APCs present small peptides 
fragments containing the T cell eptiopes on its MHC class II molecules. Th 
lymphocytes bearing the corresponding TCR recognize the peptide-MHC class II 
molecule and were then activated. Although IgE response to many food allergens has 
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been thoroughly studied, the detailed information about the T cell response to food 
proteins remains scarce. Recent studies suggest that immunotherapy on 
hypersensitivity can be associated with the downregulation of allergen-specific Th2 
cells and modulation toward a more balanced cytokine production (Akdis et al. 1998, 
Francis et al. 2003，Pene et al 1998, Secrist et al 1993, Till et al. 2004). Thus, 
detailed analysis of the T cell response against allergens, including identification of T 
cell eptiope, is an important contribution to a comprehensive characterization of 
allergenic proteins. This knowledge not only improves our understanding on the 
pathophysiology of allergic diseases, but also helps in immunotherapy development 
(Bohle 2006). T cell epitopes of some food allergens were analyzed and the number of 
epitopes found varies. The results are summarized in Table 2.1. It was also found that 
allergic food proteins contained multiple T cell-activating regions dispersed 
throughout the entire allergen molecule as compared with aeroallergens (Holen et al 
2001，Inoue et al 2001, Bohle et al 2003, Stickler et al 2003，Glaspole et al 2005). 
The epitopes recognized differs markedly between individuals and most individuals 
harbor T cells specific for more than one epitope. 
A putative T cell epitope of shrimp tropomyosin have recently been discovered 
by Subba Rao et al (1998). Six peptides were predicted as T cell epitopes on the basis 
of a computer algorithm and synthesized with a solid-phase synthesizer. These 
peptides were tested for the IgG and IgE binding properties and the ability to induce 
splenocyte proliferation. A 21-mer peptide spanning the amino acid residues 261-281 
in Met e 1 was postulated as potential T cell epitope which was able to induce in vitro 
proliferation of splenocytes isolated from mice immunized with native tropomyosin. 
The downregulation of the allergen-specific antibody responses was studied in vivo in 
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Table 2.1 T cell epitopes of food allergens in human 
Food Food allergen No. of T cell epitopes Reference 
identified 
Milk a si-casein 5-7 Bolhaar et al 2004 
Bohle et al 2005a 
/3-lactoglobuliii 4-7 Piastraera/. 1994 
Inoue et al 2001 
Egg Galdl 3-10 Nakajima-Adachi et al 1998 
Holen et al 2001 
Suzukiet al 2002 
Elsayed et al. 2004 
Gald2 1 -2 Eigenmann et al 1996 
Cooke and Sampson 1997 
Celery Api gl 7 Bohle et al 2003 
Hazelnut Cor a 1.04 20 Asero 2003 
Brazil nut Bevel 4 Stickler et al 2003 
Peanut Arah2 4-8 Burks et al 1998 
Glaspole et al 2005 
Beef BSA 3 Tanabe et al 2002 
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BALB/c mice with the synthetic peptide coded for the potential T cell epitope. After 
administrated the peptide with adjuvant to the tropomyosin sensitized mice, both 
tropomyosin- specific IgG and IgE were able to maintain at reduced titers beyond 30 
days. The reduction of the tropomyosin specific immune response may possibly be 
due to the alternation in the cytokine profiles or the activation of tropomyosin-specific 
T-suppressor cells (Kammerer et al 1997). However, the amino acid sequence of this 
potential T cell epitope is significantly different to the putative B cell eptiopes. Since 
the study of tropomyosin T cell epitope is limited, further study is needed in the 
detailed analysis of the molecular structure, conformation and physiological 
significance of these epitopes. The identification of the B and T cell eptiopes provide 
valuable information on tropomyosin allergenicity and peptide therapy in seafood 
allergy. 
2.5 Novel approaches for the treatment of food allergy 
Although the prevalence of food allergy is increasing，the current primary 
therapy for food allergy is strict avoidance of the offending food. However, avoiding 
the offending allergen is not efficient and safe as accidental consumption is almost 
inevitable. Sensitized patients may expose to the allergens by inhalation or direct 
contact. Occupational allergic reactions were documented in snow crab workers who 
experienced anaphylaxis during cooking of crabs (Malo et al 1997, Jeebhay et al 
2001). Antihistamine may partially relieve symptoms of oral allergy syndrome 
(Bindslev-Jensen et al 1991) and IgE-mediated skin symptoms but do not block 
systemic reactions. Oral corticosteroids are generally effective in treating allergic 
disorders, but the side effects of protracted corticosteroid use are unacceptable (Sogn 
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1986，Sampson 2003). Several potential therapies have been under investigation and 
most of them aim at re-establishing the balance between Thl and Th2 responses or 
blocking the interactions between IgE and mast cells. Some of them are discussed 
below. 
DNA immunization also called DNA vaccine is a novel approach by immunizing 
sensitized patients with bacterial plasmid DNA (pDNA) encoding the specific 
antigens (Li and Sampson 2002). The pDNA is injected subcutaneously and taken up 
by APC. The encoded sequence is then expressed intracellularly. The expressed 
protein is processed endogenously and presumed to present on MHC class I molecule 
rather than MHC class II molecules (Burks et al 2001). It is presumed that the 
expression of endogenous protein would trigger the activation of cytotoxic T cell 
(CTL) instead of Th cell. This then modulates the T cells immunogenicity response to 
the specific antigen. Moreover, it biases towards the Thl response by upregulating 
IFN-y and suppressing allergen-specific IgE production (Speigelberg et al 1997, 
Tighe et al 1998). Oral delivery of DNA immunization modulated peanut 
antigen-induced murine anaphylactic responses (Roy et al 1999). Intramuscular and 
intradermal injections of DNA vaccine were also demonstrated and showed the 
induction of Thl response (Li et al 1999，Raz et al 1996). 
Other than administering the DNA vaccine alone, immunostimulatory sequence 
(ISS) is used as adjuvant. ISS contains unmethylated cytosine and guanine 
dinucleotide repeat motifs (CpG motifs). The immunostimulatory effect is only 
mediated by bacterial but not vertebrate DNA. It may relate to the relative frequency 
of CpG motifs in the bacterial compared with the vertebrate genome or to the absence 
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of cytosine methylation in bacterial DNA (Tighe et al. 1998). The CpG motifs 
stimulate the APCs and natural killer cells (NK cells) to produce IFN-y and IL-12 
which promote immune deviation toward Thl phenotype (Burks et al 2001). They 
also trigger B cell to class switch to IgM synthesis. In the presence of allergen, naive 
Th cell would differentiate into Thl and produce more lESf-y which triggers B cell to 
class switch to IgG2a. As a result, the immune response deviates away from the 
allergic Th2 phenotype (Tighe et al. 1998). Co-administration of DNA vaccine and 
allergen suppress the antigen-specific IgE level and concentration of Thl cytokines, 
such as IL-4 and IL-5. The histamine level is reduced also in p-galactosidase 
sensitized mice (Nguyen et al 2001). The protective effect of ISS-ODN against the 
development of anaphylactic hypersensitivity is shown. 
Perhaps specific immunotherapy (SIT) is the only effective immunotherapy. This 
treatment involves the administration of increasing doses of allergen extracts, usually 
via the subcutaneous route (Runa Ali and Larche 2005). Over time, the individual 
becomes less reactive to the allergen, perhaps due to CD4+ T cell tolerance. It takes 
approximately three months with the ultimate goal to produce both immunological 
and clinical tolerance. SIT has been demonstrated to be effective in treating rhinitis 
(Vamey et al 1991, 1997, Bousquet et al, 1998，Durham et al 1999), insect venom 
allergy (Golden et al. 1998，Lerch and Muller 1998) and allergic asthma (Abramson et 
al 1999). SIT can be performed by injecting allergen extract or allergen peptide. 
However, traditional injection immunotherapy for food allergy is not recommended 
due to high rate of adverse systemic reactions, including anaphylaxis and death 
(Nelson et al 1997). On the other hand, peptide immunotherapy reduces the allergen 
to its component CD4+ T cell epitopes. Peptides are administered in order to induce 
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antigen specific CD4+ T cell tolerance. Peptide immunotherapy is considered as safer 
therapy than intact allergen immunotherapy because peptides cannot crosslink IgE. 
Short synthetic peptides representing T cell epitopes may be able to modulate immune 
responses to allergen, without the risk of frequent adverse events. A number of animal 
models of peptide therapy in allergic disease have been developed. Briner et al (1993) 
demonstrated the ability of allergen-derived peptides to inhibit T cell cytokine 
production and antibody responses by priming mice with the cat allergen, Fel d 1. 
Hoyne et al (1993) treated mice by intranasal administration of house dust mite 
allergen, Der p 2, peptides, resulting in the downregulation of T cell and antibody 
responses to the whole protein. T cell proliferative responses in mice were inhibited 
by administering a dominant T cell epitope of Bet v 1, the major birch pollen allergen, 
both before and after antigen priming (Bauer et al. 1997). In a model of bee venom 
allergy, mice were sensitized to the major allergen phospholipase (PL)A2 and treated 
by intraperitoneal administration of peptides covering the entire molecule (Astori et al, 
2000). Reductions in the Th2:Thl ratio and allergen specific IgE were recorded 
(Oldfield et al 2001，2002). Recent studies demonstrated clinical efficacy of 
administering appropriate doses of peptides with appropriate size and solubility. Then 
peptide immunotherapy may improve the safety and efficacy of antigen specific 
therapy in allergic diseases (RunaAli and Larche 2005). 
Th2 cytokines were demonstrated to play a central role in the pathogenesis of 
allergic asthma in numerous studies. Th2 cytokines, including IL-4, IL5 and IL-13, 
are produced from Th2 cells. IL-4 and IL-13 promote class switching of B cells to IgE 
production and activate mast cells. On the other hand, IL-5 was shown to have a 
potentially autocrine effect on mast cells and paracrine effects on eosinophils (Lorentz 
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et al 1999，Romagnani 2000b). Thl and Th2 cytokines promote the growth and 
differentiation of their subset but inhibit the growth and differentiation of the 
opposing subsets (Seder and Paul 1994). Lee et al. (2001) developed a mouse model 
of peanut anaphylaxis to show the therapeutic and preventive effects of orally 
administrated IL-12 on peanut allergy. IL-12 is a heterodimeric cytokine produced by 
APC. It promotes differentiation of Thl cells and IFN-y production but inhibits the 
differentiation of ThO cells into IL-4 secreting Th2 cells, thus suppressing the 
production of IgE (Wills-Karp 2001). Lee et al (2001) found that oral IL-12 
administered at the time of sensitization as well as three weeks after sensitization 
inhibited peanut-induced anaphylactic reactions. Symptoms attenuation was 
accompanied by a reduction of the peanut specific serum IgE levels and reduction or 
reversal of the IgGl/ IgG2a ratio. Moreover, the Thl/Th2 cytokines ratios (IFN-y/ 
IL-4 and IFN-y/ IL-5 ratios) were increased. These results suggested some potential 
for the use of IL-12, either alone or in combination with other immunomodulatory 
agents, as a treatment for peanut allergy. However, further studies are required to 
evaluate dose-related and long-term effects of IL-12 therapy on peanut 
hypersensitivity. 
Mucosal intestine is the first line of host defense by assimilating the antigens 
encountered by the enteric route. If antigen is exposed in high level during first few 
months of life, it may predispose individuals into allergic sensitization. Intestinal 
inflammation may increase the sensitization of a subject. Microflora is an important 
constituent of the gut mucosal barrier in the intestine (Majamaa and Isolauri 1997). 
Probiotics are live bacteria or their components that have beneficial effects on the 
health and well-being of the host. Probiotic bacteria are able to reinforce gut defense 
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by improving the intestinal microflora balance and enhancing the immunity (Isolauri 
1997). The concept of probiotic foods, in which beneficial bacteria were regarded as 
food supplements, was introduced more than 100 years old by Fuller (Li and Sampson 
2002，Wegrzyn 2003). The major source of probiotics is in the form of diary-based 
foods containing lactobacilli and bifidobacteria. Majamaa and Isolauri (1997) reported 
a clinical study in infants and young children with cow's milk hypersensitivity. They 
showed that after two months treatment with Lactobacillus rhamnosus GQ the 
concentrations of proinflammatory cytokines (TNF-y & ECP) were decreased. It had 
alleviated the severity of atopic dermatitis symptoms. Kalliomaki et al (2001) 
showed that Lactobacillus GG could prevent the early atopic disease in infants at high 
risk. Some expectant mothers, who had at least one first-degree relative or partner 
with history of atopic disease, were fed with Lactobacillus 2-4 weeks before delivery. 
Then it was continued to be fed to the infants for six months after birth. At two years 
old, the frequency of atopic eczema in the probiotic-treated group (23%) was half that 
of the placebo group (46%). Although the mechanism of the effects of Lactobacillus 
GG was not clear, a recent report from Pessi et al. (2000) showed that it had 
anti-allergic inflammatory properties. Thus probiotics could be used to treat intestinal 
inflammation too. 
IgE plays an important role in the allergy response and thus is one of the targets 
to interrupt the allergic response. IgE antibodies bind to the Fc receptors (FceRJ and 
FcsRII) on mast cells and are then cross-linked by the allergens. The monoclonal 
anti-IgE antibodies are synthesized by immunizing the mice with human IgE. They 
recognize the constant region of IgE, the same site at which IgE interacts with the 
FceR. Thus, they block the binding between the IgE and the mast cells and inhibit the 
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release of mediators. These monoclonal anti-IgE antibodies can only bind to the free 
IgE and not to IgG or IgA. They cannot bind to basophils- or mast cells-bound IgE, so 
that no cross-linking would occur. Decreased level of IgE results in downregulation of 
FcsRI receptor expression on mast cells and basophils (Wegrzyn 2003), reduction of 
histamine release and inhibition of IgE production (Casale et al. 1997). Several 
studies were focused on the use of rhuMAb-E25 to treat allergic asthma and rhinitis 
(Milgrom et al 1999, Barnes 1999，Casale et al 1997). They showed that the use of 
rhuMAb-E25 led to the decrease of serum allergen specific free IgE level. 
Corticosteroids were used to control the asthma. Milgrom (1999) showed that more 
individuals in the treatment groups could reduce the dose of oral and inhaled 
corticosteroids and higher rates of discontinuation of these drugs than in the placebo 
group. Both of them suggested that the therapy of anti-IgE was well tolerated and safe 
for long term administration. 
Traditional Chinese medicine has been widely used in Asia for few centuries. 
Recently, it attracted more interest in western countries because of its reputed 
effectiveness, low costs and the relative absence of side-effects (Li and Sampson 2002， 
Wegrzyn 2003). A food allergy herbal formula-1 (FAHF-1) which consisted of 11 
herbs was investigated by Li et al (2001) to treat peanut allergy. It showed that 
FAHF-1 reduced the peanut-specific IgE concentration and blocked peanut-induced 
anaphylactic symptoms. The mast cell degrandulation and plasma histamine levels 
were also reduced. FAHF-1 significantly suppressed peanut-specific T-cell 
proliferation and Th2 cytokine production, e.g. IL-4, IL-5 and IL-13. No toxic effects 
on liver or kidney functions and immune suppression were shown. The use of Chinese 
medicine for allergy therapy will draw more attention. 
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Chapter 3 
Expression of shrimp recombinant tropomyosin 
& 
Sensitization of mice 
3.1 Introduction 
With the fast development of molecular biology, lots of modified foods and 
transgenic crop products have been developed and some novel gene products which 
are allergenic may be produced. However, research on food allergy in allergic patients 
is limited because accessing or investigating cell functions and associated processes 
involved in the lymphoid organs are impossible. In addition, due to the ethical and 
efficacious reasons, sensitization studies in human are not allowed (Knippels et al. 
2000). Therefore, animal models which mimic the allergic responses of human could 
provide a useful tool to expand the knowledge of mechanisms and to identify new 
therapeutic strategies. 
The earliest use of animals for allergic enteropathy began in 1963 by Dr. Mota 
who demonstrated the capacity to sensitize rats by the simultaneous injection of 
antigen and Bordetella pertussis vaccine (Mota 1963). However, animal model was 
seldom used in studies of food allergy until 1970s. In the past decade, several animal 
models, for example, guinea pig, rat and mouse have been developed for research on 
several food allergens. The use of animal models in food allergy has been reviewed by 
a number of research groups (Buchanan and Frick, 2002; Helm 2002; Helm and Burks, 
36 
2002; Tang et al 2003). Different animals were used as models on food allergy by 
different studies. Guinea pig has been extensively used for the investigation of infant 
milk formulas (Boner et al 1992，Coombs et al. 1978，Devey et al 1976，Piacentini et 
al 1991，Zeuger 1990). Boner et al (1992) suggested that whey hydrolysate formula 
has lower anaphylactic ability than the pasteurized cow milk and conventional cow 
milk infant formula. Since the immune system of guinea pig is less defined than rat 
and the immunological and biochemical tools in studying this model are insufficient, 
rat is more commonly used for studying food allergy. Between different strains of rats, 
Brown Norway rats have been widely used to investigate milk sensitive allergy 
(Atkinson and Miller 1994) because they are easier to be sensitized. The milk 
allergens recognized by this model are found to be the major allergens causing 
problem in human. Knippels et al (2000) used this model to study the IgE response of 
hen's egg white protein and cow's milk. The result showed that some allergens were 
common between those proteins. Mice are the most popular animals for studying food 
allergy. C3H/HeJ mice exhibited similar pattern of allergic symptoms to human when 
sensitized with peanut allergen. Moreover, mice sera IgE identified Ara h 2，one of the 
major peanut allergens, with epitopes similar to those identified by human sera (Li et 
al. 2000). Another mice strain, BALB/c mice, was used for demonstrating the role of 
cytokines in the regulation of food allergy (van Halteren et al 1997). OVA sensitized 
mice showed decrease in IgE and histamine levels after oral challenge if they are 
treated with antibodies against IL-4 or IL-10. This study showed the important 
correlation between Th2 cytokines, IgE production and histamine release. 
Furthermore, BALB/c mouse was also used in others studies to demonstrate the 
genetic factor of allergy (Kweon et al. 2000)，the sensitization methods (Burks et al. 
1994，Dearman and Kimber 2001) and the way of food allergen exposure (Hsieh et al 
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2003). 
Instead of using small animal models, dog and pig which more closely mimic 
human physiology, anatomy and allergic diseases have been used for food allergy 
investigation. A pig model of peanut allergy that mimics allergic symptoms and 
histological profile of human peanut allergy was developed by Helm et al. (2002). 
Although the high physiological and immunological similarity between pig and 
human, the research area is restricted due to the limited knowledge of pig immune 
system. For dog, recent works on wheat and milk allergy using dog as the model were 
summarized (Buchanan and Frick 2002). Pups sensitized with wheat or cow's milk 
exhibited vomiting and diarrhea, positive skin test and produced specific IgE 
antibodies. The major allergens of these proteins in dog were found to be the same as 
in human. However, as result of the high operating cost and the small number of 
animal centers with large animal facilities, large animals are not usually used as 
model (Tang et al 2003). Between all of the animals mentioned before, mouse is the 
most common one used for food allergy. In addition of the well defined immune 
system, the small size of mouse leads to a relatively lower operating cost than that of 
other animals. 
The use of BALB/c mice as murine model for studying shrimp allergy was 
developed by our laboratory (Tang, 2004). Tang's study showed mice immunized with 
recombinant tropomyosin in 0.1 mg or 1 mg developed signs of allergic responses, 
including scratching around the snout, body and tail. The snouts of mice fed with 
tropomyosin swelled. Sera from mice fed with tropomyosin gave positive result in 
passive cutaneous anaphylaxis assay and splenocytes proliferated significantly in vitro 
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from mice fed with tropomyosin. Histological sections showed that inflanimation of 
small intestines was incurred in mice fed with tropomyosin. But it showed that 
tropomyosin-specific IgE was only induced significantly in mice fed with 0.1 mg but 
not 1 mg tropomyosin. In addition, production of IL-2 and IL-4 by splenocytes 
re-stimulated with tropomyosin in vitro was significantly higher in mice fed with 0.1 
mg tropomyosin rather than those fed with 1 mg tropomyosin. This study identified 
that oral sensitization of mice with shrimp tropomyosin could elicit antigen specific 
humoral and cellular responses to the immunized food antigen. Thus, BALB/c mice 
were used for investigating shrimp antigen epitopes in the current study. Tang's study 
also identified that 0.1 mg tropomyosin was the optimal antigen concentration for 
shrimp allergy sensitization. Since mice fed with 0.1 mg tropomyosin could induce 
significantly higher tropomyosin-specific IgE than feeding with other tropomyosin 
concentrations, mice were sensitized with 0.1 mg tropomyosin in the current study. 
The objectives of this chapter are to produce Metapenaeus ensis tropomyosin by 
recombinant technology and sensitize the mouse model for epitopes mapping 
(Chapter 4). Metapenaeus ensis is a common and economically important shrimp 
species in Hong Kong. The tropomyosin cDNA of Metapenaeus ensis was isolated by 
Leung et al. in 1994. The clone was originally expressed in a glutathione-S 
transferease (GST) plasmid system for the production of recombinant protein. Since 
the large molecular size (29 kDa) of the GST may alter the conformation of 
tropomyosin, Tang (2004) subcloned the tropomyosin cDNA into His-tag expression 
vector pQE30. The six consecutive histidine molecules were used as tag because of 
their small molecular size and poor immunogenicity. The tropomyosin encoded 
plasmids were transformed into E. coli for recombinant protein expression. Expressed 
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recombinant tropomyosin was purified and quantified. BALB/c mice were fed with 
the recombinant tropomyosin with the aim to elicit the allergic response to shrimp 
tropomyosin. After several times of sensitization, the mice were challenged with 
higher dose of recombinant tropomyosin. Blood was then collected for blood 
tropomyosin-specific IgE determination. Mice with relative highly level of 
tropomyosin-specific IgE levels were considered to have tropomyosin allergy and 
would be used for tropomyosin epitope mapping study in the following chapter. 
In the current study, two different feeding protocols are used. The first feeding 
protocol in which mice are fed with tropomyosin in weekly basis is the same as Tang 
(2004) did. In our preliminary results, the IgE level of mice fed with tropomyosin 
using this feeding protocol showed no significant difference from that of mice fed 
with PBS. This result indicated that the mice have not successfully sensitized with 
tropomyosin allergy. Then a second feeding protocol is developed. The major 
difference of the two protocols is the period between the first and second 
sensitizations. In the second protocol, longer duration is used between the two 
sensitizations. This can reduce the chance of tolerance in mice which might be the 
reason why mice fed with the first protocol cannot be sensitized. 
3.2 Materials and Methods 
3.2.1 Recovery of E, coli with txopomyosin-carrying plasmid 
E. coli Ml 5 containing the plasmid with Metapenaeus ensis tropomyosin 
(Met e I) gene was picked out from the glycerol stock. The cells were streaked on 
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LB-agar plate containing 25 i^g/ml kanamycin and 100 jag/ml ampicillin and 
incubated at 37°C overnight. Single colony was inoculated in 20 ml LB medium 
containing 25 jag/ml kanamycin and 100 |j,g/ml ampicillin and incubated at 37°C 
overnight with shaking for cell growth. 
3.2.2 Preparation of tropomyosin-carrying plasmid 
10 ml overnight cultures of E. coli were centrifuged at 5000 x g for 10 
minutes. Pelleted bacteria was resuspended in 250 jxl of Buffer PI and transferred to 
microcentrifuge tube. 250 jil of Buffer P2 was added and mixed by inverting the tube 
for 4 - 6 times. 350 |j1 of Buffer N3 was added and then centrifuged at 13000 x g for 
10 minutes. Supematants were saved and transferred to the QIAprep spin column. The 
column was centrifuged for 30-60 seconds and the flow-through was discarded. The 
column was then washed with 0.75 ml Buffer PE and centrifuged for 30 — 60 seconds. 
The flow-through was discarded and the column was centrifuged for 1 more minute. 
Lastly, 50 pi of ddHaO was added and plasmid was collected by centrifugation. 
3.2.3 Confirmation of DNA sequence of the tropomyosin 
The size of the tropomyosin gene inserted in the plasmid was confirmed by 
PGR. The PGR mixture for amplification included 2 of 15 mM MgCl2 PGR buffer 
(lOX)，0.4 yd of deoxynuxleotide triphosphate mix (dNTPs, 10 mM each), 0.4 \i\ of 
Taq polymerase, 0.4 [xl of each sequencing primer solution (10.0 |jM) and 1 \il of 
plasmid DNA. The PGR product was then analyzed by 1.5% agarose gel 
electrophoresis. The nucleotide sequence of the sequencing primers and the profile for 
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PGR were as follows: 
Sequencing primers: 
Type IV-For 5 ' -CGG ATAACAATTTCACAC A G - 3’ 
Type IV-Rev 5 ' - GTT CTG AGG TCATTACTG G-3， 
The profile of PGR cycle was as follows: 
5 minutes at 96°C for denaturation, followed by 25 cycles of 1 minute of 
denaturation at 96°C, 1 minute of annealing at 56°C, 1 minute of extension at 
72°C and final extension for 10 minutes at 72°C. 
4 |j1 of plasmid were sequenced using the Dye Terminator Cycle 
Sequencing Ready Reaction Kit (Applied Biosystems, Part No. 4020790). The 
sequencing procedures were as follows: 
Cycle sequencing: 
The sequencing reaction mixture was prepared as follows: 
Terminator Ready Reaction mix 8.0 |j,l 
Template (Plasmid) 4.0 
Primer (one of the primers used in PGR) 3.2 pmole 
Add deionized H2O to final volume 20 jil 
Thermal cycler (Bio-Rad Cat. No. 170-8720) was used for cycle sequencing. 
The cycling profile was as follows: 
1 minute at 96°C for denaturation, 25 cycles of 10 seconds at 96°C, 5 
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seconds at 50°C, and 4 minutes at 60°C, and then kept at 4°C. 
The sequencing reaction mixture was then analyzed on ABI 310 Genetic 
Analyser (Applied Biosystems). 
3.2.4 Induction of the recombinant protein 
10 ml of the overnight culture grown from the single colony was inoculated 
into 500 ml LB medium containing 25 jxg/nil kanamycin and 100 |ig/ml ampicillin at 
37°C with shaking until the ODeoo had reached 0.6. IPTG was added into the culture 
medium to a final concentration of 1 mM and incubated overnight for induction of 
recombinant protein. The cells were harvested by centrifugation at 10,000 x g for 20 
minutes. Supernatant was discarded and the cell pellet was then stored at -20°C. The 
above steps were repeated six times to collect a larger cell pellet. 
3.2.5 Purification of the recombinant protein 
The purification steps were modified from the instructions provided by the 
Qiagen QIAexpress Type IV Kit (Qiagen, Cat. No. 32149). Briefly, the cell pellet was 
thawed at 4°C for 1 hour and resuspended in lysis buffer (6.90 g NaHzPCU.HzO，17.54 
g NaCl and 0.68 g imidazole in 1 L ddE^O at pH 8.0) at 2-5 ml per gram of cell pellet. 
1 mg/ml of lysozyme was added to the mixture and incubated for 30 minutes at 4°C 
with stirring. Then the mixture was sonicated and centrifuged at 10,000 x g for 30 
minutes at 4°C to pellet the cellular debris. The supernatant was saved for further 
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purification. 
The lysate was added to 50% Ni-NTA slurry (lysate : Ni-NTA = 4:1) and 
mixed gently by shaking in 5 ml column at 4°C for 1 hour. The bottom cap and the 
top-adapter were removed and the lysate was allowed to elute out. 1 ml of lysate was 
collected for SDS-PAGE analysis (section 3.2.6). The Ni-NTA slurry was washed 
with 4 ml of washing buffer (6.90 g NaHzPO^.EbO，17.54 g NaCl and 1.36 g 
imidazole in 1 L ddHzO at pH 8.0) twice. 1 ml of the washing buffer eluted out was 
collected for SDS-PAGE analysis. Lastly, 1 ml of elution buffer (6.90 g 
NaH2P04.H20, 17.54 g NaCl and 17.00 g imidazole in 1 L ddHzO at pH 8.0) was 
added and the eluent was collected. The column was eluted with 1 ml of elution buffer 
for 5-6 times more. 
3.2.6 Sodium dodecyl sulfate polyacrylamide gel eletrophoresis (SDS-PAGE) 
The Mini-PROTEAN 3 cell (Bio-Rad, Cat. No. 165-3301) was set up 
following manufacturer's instructions. Protein samples were analyzed on 4% stacking 
(1.25 ml 0.5 M Tris at pH 6.8，2.85 ml ddHzO, 50 10 % SDS, 37.5 jil 10% 
ammonium persulfate, 0.85 ml 40% acrylamide/bis solution 19:1 and 5 i^l TEMED 
[N’N，]S[’，N，- tetramethylethylenediamine]) and 12.5% separating gel (2.5 ml 1.5 M 
Tris at pH 8.8，4.85 ml ddHaO，100 10% SDS, 75 i^l 10% ammonium persulfate, 
4.25 ml 40% acrylamide/bis solution 19:1 and 10 |il TEMED). 
10 |il of each protein sample was mixed with 10 |j,l 2X sample buffer (3.0 g 
Tris，14.8 g EDTA，4 g SDS, 10 ml 2-mercaptoethanol, 20 ml glycerol, 40 mg 
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bromophenol blue in 100 ml ddH20 at pH 6.8) and heated at 96°C for 10 minutes. 
Molecualr weight marker (Bio-Rad, low range SDS-PAGE standard, Cat. No. 
161-0304) was run together with protein samples for size estimation. The denatured 
protein samples were loaded into the gel and ran at 120 V in IX SDS-PAGE electrode 
running buffer prepared from lOX SDS-PAGE electrode running buffer (30.3 g, 10 g 
SDS，137.3 g glycine in 1 1 ddHsO) until the frontline of the bromophenol blue 
reached the bottom of the gel. 
The polyacrylamide gel was stained with staining solution (2.5 g brilliant 
blue R [Sigma, B-8647, Lot 98H9313]，70 ml acetic acid and 400 ml methanol in 
1000 ml ddHzO) for 20 minutes with shaking. It was then destained with destain 
solution I (500 ml methanol, 100 ml acetic acid in 1 1 ddHiO) and destain solution II 
(50 ml methanol, 70 ml acetic acid and 1 1 ddHaO) for 20 minutes each with shaking. 
Lastly, cleaning solution (10% acetic acid, e.g. 100 ml acetic acid in 1 L ddHsO) was 
added and tissue paper was put at the side of the destain box to absorb the excess stain. 
After overnight cleaning, it was rinsed with water and sealed with plastic wrap. 
3.2.7 Concentration measurement of the recombinant tropomyosin 
Bovine serine albumin (BSA) (Sigma, Cat No. B-0914) was used as 
standard in determining the concentration of the tropomyosin by comparing their 
absorbance. The BSA was diluted to different concentrations (0 mg/ml to 1 mg/ml) by 
PBS as manufacturer's instruction. Bicinchoninic acid solution (BCA solution) 
(Sigma, Cat. No. B-9643) was freshly prepared by mixing bicinchoninic acid and 
copper II sulfate (Sigma, Cat No. C-2284) (bicinchoninic acid : copper II sulfate = 50 : 
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1). B C A solution was added to the standard and the samples (BCA solution : sample = 
1:1) and incubated at 37°C for 30 minutes. OD561 was measured and the concentration 
of the samples was estimated from the BCA standard curve. 
3.2.8 Mice 
Three to four weeks old female BALB/c mice were acquired from the 
Laboratory Animal Services Centre, The Chinese University of Hong Kong and used 
in the experiments. Standard guidelines for animal care and use of animal were 
followed. The animal experiments were approved by the review board of The Chinese 
University of Hong Kong and the Department of Health, Government of Hong Kong 
Special Administrative Region. 
3.2.9 Mice sensitization and challenging 
Four groups of mice were included in this experiment with 3 to 15 mice in 
each group (Table 3.1). For each mouse, 10 jag of cholera toxin (Sigma, Cat. No. 
C8052) was used as adjuvant. In the experimental group, mice were fed with 0.1 mg 
tropomyosin with adjuvant. In the three control groups, mice were fed with 0.1 mg 
cell lysate，0.1 mg His-tag peptides or PBS. 10 \ig of cholera toxin per mouse was 
also used in these control groups. Cell lysate was prepared by expressing E. coli 
containing the vector pQE-30 without insert of tropomyosin D N A . The expression 
and purification of the cell lysate was similar to tropomyosin as described above. All 
materials used to feed the mice were dissolved in 350 \il PBS. Ix PBS was prepared 
from lOx stock (14.26 g Na2HP04.2H20，80.0 g NaCl, 2.0 g KH2PO4 and 2.0 g KCl 
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in 1 1 ddH20). Cell lysate was used because the recombinant tropomyosin was 
inserted into the vector pQE-30. Since all materials were dissolved in PBS for mice 
feeding, PBS was used as a control. All mice were sensitized four times with 
tropomyosin, cell lysate, His-tag peptides or PBS and challenged with 1.0 mg 
tropomyosin. 
Tropomyosin and other feeding agents were fed to mice intragastically by a 
25G stainless steel blunt feeding needle. As discussed in the introduction, section 3.1, 
preliminary results showed that there was no significant difference in IgE level 
between mice sensitized weekly with tropomyosin and control groups. Then in this 
experiment, two separate protocols were used for mice sensitization with tropomyosin. 
According to Tang's (2004) method, the mice were sensitized regularly in one-week 
interval for three weeks. At the fourth week, the mice were fasted overnight and 
challenged with 1.0 mg tropomyosin (Fig. 3.1，A). The second protocol was similar to 
the previous one, but with slightly modification. Instead of sensitized on a weekly 
basis, the mice were sensitized 12 days after the first sensitization. After then, the 
mice were continued to be fed at one-week interval. At day 32, the mice were fasted 
overnight and challenged in the following day (Fig 3.1，B). Two different protocols 
were used for mice sensitization with tropomyosin and PBS, but only the first 
protocol was used for mice sensitizated with cell lysate and His-tag peptides (Table 
3.1). 
3.2.10 Tropomyosin-specific IgE level in blood 
Blood was drawn from tail of mice at day 0，14，21 (after sensitization) and 
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28 (after challenge) in the first sensitization protocol or 0, 19，26 (after sensitization) 
and 33 (after challenge) in the second sensitization protocol (Fig 3.1). The blood was 
centrifuged at 14,000 x g at 4°C for 10 minutes. Supematants were collected and 
centrifuged for two more minutes. Sera (the supernatant) were collected and stored at 
-20°C for ELISA. 
Tropomyosin-specific IgE level was detected by Enzyme-Linked 
Immunosorbent Assay (ELISA) and each serum sample was done in duplicate. 10 
|ig/ml of recombinant tropomyosin in coating buffer (0.80 g NaaCOg，1.46 g NaHCOs 
and 0.10 g NaNs in 500 ml ddHiO at pH 9.6) was coated in Nunc-immuno 96-well 
flat bottom plates at 4°C overnight. The plates were washed with PBS twice and 
blocked with blocking buffer (3.0% bovine serum albumin (BSA) in PBS) at room 
temperature for 2 hours. They were washed with PBS in 0.05% Tween 20 twice. Sera 
of mice were diluted with blocking buffer in 1:10 and incubated at 4°C overnight. The 
plates were washed with PBS in 0.05% Tween 20 for four times. The secondary 
antibody, Biotin antimouse IgE (BD Biosciences PharMingen, Cat. No. 553419), was 
diluted with blocking buffer to 1 |xg/ml and incubated at room temperature for 45 
minutes in the dark using aluminum foil. The plates were then washed with PBS in 
0.05% Tween 20 for six times. Avidin-peroxidase (Pierce, Cat No. 29994) was 
diluted to 1 pig/ml with blocking buffer and incubated at room temperature for 30 
minutes in the dark. The plates were lastly washed with PBS in 0.05% Tween 20 for 
eight times. 2,2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) (Sigma, Cat. 
No. A1888) solution (0.05% ABTS, 0.03% H2O2, 0.24 M citric acid monohydrate and 
0.05 M Na2HP04 at pH 4.2) was added as substrate and incubated in the dark. The 
color intensity developed was measured using a microplate reader at OD420 within 30 
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minutes. 
3.2.11 Statistical analysis 
The statistical significance of the blood tropomyosin-specific IgE levels 
obtained was determined using SYSTAT software (SigmaStat, version 3.10). 
Tropomyosin-specific IgE at the same time point were analyzed by Student's t-test if 
they met the assumptions for normality and homocedasticity. Otherwise, 
Mann-Whitney Rank Sum Test was used. Data were expressed as mean 土 SE 
(standard error) and differences between groups were considered significant at P value 
<0.05. 
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Table 3.1 Groups of mice in experiments. 
Number of mice 
Groups Treatment First * Second * 
Experimental group Tropomyosin 0.1 mg 8 15 
recombinant 
tropomyosin 
Cell lysate 0.1 mg cell lysate 6 
Control groups His 0.1 mg His-tag 3 
peptides 
PBS ** PBS 3 3 
* First: Feeding of mice using the first feeding protocol 
Second: Feeding of mice using the second feeding protocol 
*• PBS: Phosphate buffered saline 
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A. First feeding protocol 
Sensitization Challenge 
n i i i V 
0 7 14 21 28 
B. Second feeding protocol 
Sensitization Challenge 
M 
- i l l V 
— L -J 
0 12 19 26 33 
DAY 
^ Sensitization 〉〉 C h a l l e n g e |[]| 〉Bleeding 
Fig. 3.1 Experimental protocol. BALB/c mice were sensitized orally with recombinant 
tropomyosin at one week-interval (first sensitization protocol) (A) or 
following the second sensitization protocol in which the first and second 
sensitization was 12 days apart (B). The mice were sensitized four times 
before challenged. Four different treatment groups were shown in Table 4.1. 
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3.3 Results 
3.3.1 D N A sequence of the cloned tropomyosin 
After the E, coli Ml5 was recovered from the glycerol stock and grown up 
in the LB medium, plasmid was prepared. The size of the tropomyosin insert was 
confirmed by PGR. Gel electrophoresis of PGR product showed that there was a 
single band with size around 1000 bp (Fig. 3.2). Then the plasmid was used for 
sequencing reaction to ensure there is no mutation in the nucleotide base. The 
nucleotide sequence of the tropomyosin was found to be identical to the shrimp 
Metapenaeus ensis tropomyosin D N A published before by our laboratory (GeneBank 
accession number U08008). The nucleotide sequence of the Met e 1 is shown in Fig. 
3.3. The sequencing product was about 970 bp in size, consistent with the size of the 
PGR product containing the sequencing primers. 
3.3.2 Expression and purification of tropomyosin 
The expressed protein was purified by the Qiagen QIAexpress Type IV Kit. 
Sample after each step was collected for SDS-PAGE analysis. The SDS-PAGE is 
shown in Fig. 3.4. A band with size about 34 kDa was induced after the addition of 
IPTG to the culture medium. Since the expressed protein was a His-tag fusion protein, 
it could bind to the Ni-NTA slurry and retained in the column. Thus in the SDS-PAGE, 
no band with protein size in about 34 kDa was shown in the washing buffer collected 
after the first two washing steps. The recombinant protein was eluted out with some 
small proteins in the elution buffer. After further purification by dialysis, the 
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impurities were removed and the recombinant protein shown as a single band with 
size of 34 kDa. It was consistent with the result of Leung et al (1994). 
3.3.3 Hypersensitivity symptoms after challenge 
Systematic anaphylactic symptoms were evident in mice fed with 0.1 mg 
tropomyosin with adjuvant 30-45 minutes after challenge. The initial reaction 
included scratching the whole body including the sole of the foot and rubbing around 
the nose. The scratching and rubbing behavior lasted for about ten seconds in mice 
fed with 0.1 mg tropomyosin although occasional scratching (less than two seconds) 
was observed in mice fed with PBS, His-tag peptides or cell lysate. Swelling at the 
snout was observed in mice fed with tropomyosin after challenge (Fig 3.5 B) and no 
swelling was seen in control groups (Fig. 3.5 A). Some mice fed with tropomyosin 
showed reduced activity or decreased in speed of activity with increased respiratory 
rate after challenge. No other anaphylactic symptoms were observed. The scratching 
and rubbing behavior were less frequent and the duration was shorter when mice were 
sensitized according to the first feeding protocol, i.e. sensitized every seven days, than 
those sensitized 12 days apart from the first sensitization. 
3.3.4 Blood tropomyosin-specific IgE level 
To determine tropomyosin-specific IgE response, sera from each group of 
mice were obtained after intragastric gavage sensitization and four hours after 
challenge (Fig. 3.6). Tropomyosin-specific IgE concentration increased from day 14 
through day 28 in mice sensitized with tropomyosin in the first feeding protocol (Fig. 
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3.6 A) and from day 19 through day 33 in mice sensitized with tropomyosin in the 
second feeding protocol (Fig. 3.7). Tropomyosin-specific IgE levels were significantly 
higher in the mice sensitized with tropomyosin followed the second feeding protocol 
than those followed the first feeding protocol. Fig. 3.8 showed that the 
tropomyosin-specific IgE levels after the fourth sensitization and challenge in mice 
sensitized with the second feeding protocol were higher than those sensitized with the 
first feeding protocol. Tropomyosin-specific IgE levels in control mice groups, PBS 
(Fig. 3.6 A; 3.8), cell lysate (Fig. 3.6 B) and His-tag peptides (Fig. 3.6 C) were 
remained low after challenge. 
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Marker 1 2 3 Marker 
lOOObp lOOObp 
• 1 
Fig. 3.2 Agarose gel showing the PGR product of recombinant Met e 1 using 
sequencing primers. 
Lanes 1-3: PGR product; Marker: 100 bp ladder 
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1 aattcattaa agaggagaaa ttaactatga gaggatcgca tcaccatcac catcacggat 
61 ccgaattctg cggccgccag gcgatgaagc tggagaagga taacgccatg gacagggcgg 
121 atacccttga acagcagaac aaggaggcca acaacagggc tgagaagagc gaggaggagg 
181 ttcacaatct tcagaagagg atgcagcagc ttgagaacga ccttgatcag gtgcaggaat 
241 ccttgctgaa ggcaaacaac cagctcgtgg agaaggacaa ggccctctct aacgctgagg 
301 gtgaggttgc tgctcttaac cgccgcatcc agctgctcga ggaggacctg gagcgctctg 
361 aggaacgcct caacaccgcc accaccaagc tggctgaggc ctcccaggcc gccgacgagt 
421 ccgagcgcat gcgcaaggtg ctcgagaacc gctccctttc cgatgaggag cgcatggacg 
481 ccctggagaa ccagctcaag gaggcccgct tcctggctga ggaagccgac aggaaatacg 
541 acgaggttgc ccgtaagctg gccatggttg aggccgacct tgagcgtgct gaagaacgtg 
601 ctgagactgg tgaatcaaag atcatggttg aggaggaaga actgcgtgtc gttggcaaca 
661 acctgaagtc tcttgaggtt tccgaggaga aggctaacca acgcgaagag gcctacaagg 
721 agcagatcaa gaccctgacc aacaagctga aggcggctga ggctcgcgct gagttcgccg 
781 agaggtctgt gcagaagctc cagaaggagg tcgacaggct cgaagacgaa ctggttaacg 
841 aaaaggagaa gtacaagtcc attaccgacg agctggacca gactttcagc gaactgtctg 
901 gctacggtac cccgggtcga cctgcagcca agcttaattag ctgagcttgg actcctgttg 
961 atagat 
Fig. 3.3 Nucleotide sequence of the Metapenaeus ensis tropomyosin {Met e 1) in 
pQE30. The cDNA of Met e I was in red and the six consecutive histidines 
were in blue. The start codon was underlined and the stop codon was in 
bold. 
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Fig. 3.4 SDS-PAGE showing the recombinant protein obtained after induction and 
purification. Lane 1: Bacterial cells culture after expression induction by 
IPTG; Lane 2: Supernatant after cell sonication and centrifugation; Lane 3: 
Lysate collected after mixing the cell lysate and Ni-NTA slurry; Lane 4: 
Eluent collected after first wash; Lane 5: Eluent collected after second 
wash; Lane 6: Eluent collected after adding elution buffer; Lane 7: 
Recombinant tropomyosin obtained after dialysis; Marker: Low range 





Fig. 3.5 Sensitized mouse showed hypersensitivity reaction as swelling of snouts 
after challenge. A: a naYve BALB/c mouse before experiment. B: 
Tropomyosin-sensitized BALB/c mouse experienced hypersensitivity 
reaction after challenge. 
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Fig. 3.6 Induction of tropomyosin-specific IgE in BALB/c mice with feeding 
protocol 1. Blood from different groups of mice were collected on days 0， 
14，21 and 28. The tropomyosin-specific IgE levels were determined by 
ELISA. Data are expressed as mean 土 SE. * p < 0.05, significant 
difference between tropomyosin sensitized mice and the PBS control. The 
tropomyosin specific IgE in mice fed with 0.1 mg cell lysate or 0.1 mg 
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Fig. 3.7 Induction of tropomyosin-specific IgE in BALB/c mice with feeding 
protocol 2. Blood from different groups of mice were collected on days 0， 
19，26 and 33. The tropomyosin-specific IgE levels were determined by 
ELISA. Data are expressed as mean 土 SE. * p < 0.05，significant 
difference between tropomyosin sensitized mice and the PBS control. 
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Fig. 3.8 Tropomyosin-specific IgE in BALB/c mice fed with 0.1 mg tropomyosin 
according to the two different feeding protocols. Blood from different 
groups of mice were collected after sensitization and challenge. The 
tropomyosin-specific IgE levels were determined by ELISA. Data are 
expressed as mean 土 SE. * p < 0.05, significant difference between 
tropomyosin sensitized mice fed with feeding protocol 2 and feeding 
protocol 1 at the same time of sensitization. 
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3.4 Discussion 
The recombinant tropomyosin expressed in E. coli cells was a fusion protein 
conjugated with six histidines. During purification, the recombinant tropomyosin 
might be eluted together with E. coli proteins which bound to the Ni-NTA slurry. To 
ensure that the allergic response and the tropomyosin-specific IgE increment of the 
mice were the effects of tropomyosin only, different treatment groups were used (Fig. 
3.6). Antigen-specific IgE is a major indicator of food allergy as it can initiate a series 
of allergic reactions. This experiment was mainly focused on the tropomyosin-specific 
IgE to determine the efficiency of mice sensitization. The level of 
tropomyosin-specific IgE produced in mice fed with tropomyosin increased gradually 
during the sensitization period and increased to maximum after challenge at day 28 in 
the first feeding protocol. In contrast, the tropomyosin-specific IgE levels detected in 
mice fed with cell lysate or synthetic His-tag peptides did not increase much after 
challenge. The higher tropomyosin-specific IgE level in mice fed with tropomyosin 
suggested that the IgE produced was the result of tropomyosin introduction and the 
mice were sensitized to tropomyosin. 
From the experiment, we found that the level of tropomyosin-specific IgE in 
mice sensitized with tropomyosin was not significantly higher compared to it in 
control mice groups which were sensitized with histidine, lysate and PBS in the first 
feeding protocol. In addition, large variance among mice in the experiment group was 
found. Thus, another feeding protocol was designed. The length of separation between 
the first and second sensitization was the main difference between the two feeding 
protocols. The longer duration (12 days) between the first and second sensitization 
seemed to be more effective in mice sensitization. Significantly higher 
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tropomyosin-specific IgE level was produced in mice fed using the second feeding 
protocol after the fourth sensitization at day 26 and challenge at day 33 (Fig 3.7). The 
lower tropomyosin-specific IgE level detected in mice fed with the first feeding 
protocol (Fig. 3.8) may be the result of tolerance or the delay of T cell response. 
Tolerance is an active state of unresponsiveness by lymphoid cells to a particular 
antigen as a result of the cells' interaction with that antigen. Prior exposure of the 
particular antigen led to the immunologic tolerance. Although administration of 
antigen in low doses repetitively or in large quantities can induce immunologic 
tolerance in an adult, it is much more difficult than introducing tolerance in newborn 
since the immune systems is fully developed in adult. In the first feeding protocol, the 
duration between the first and second sensitization might be too short and the immune 
systems was not mature enough. Then under repetitive feeding within a short time, the 
tropomyosin molecules took up by the intestine would be wrongly recognized as 
self-protein and the immune response to this foreign antigen was suppressed. Oral 
tolerance was raised. As a result, even further sensitization, the tropomyosin-specific 
IgE production was suppressed and no allergic reaction was initiated. Although the 
time for the first sensitization in both feeding protocols was the same, three weeks 
after birth, mice which fed using the second protocol were bom for nearly 5 weeks 
when sensitized again. The immune systems might have become mature and the 
tropomyosin molecules were treated as foreign antigen. In addition to tolerance, the 
delay of time for the production of IgE after the first allergen exposure may also 
account for the low tropomyosin-specific IgE level. After the offending antigen is 
taken up and processed by APC, a series of reactions occur before producing the IgE. 
These reactions involve T cells, B cells and different kinds of interleukins, e.g. IL-4 
and IL-13. Since there is a time lag for the initiation of T cell response, the production 
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of IgE might have been delayed for more than a week after the first exposure. Thus at 
the second sensitization of the first protocol, the IgE had not produced yet and thus 
the tropomyosin-specific IgE remained at a low level. In the second protocol, the 
second sensitization was 12 days after the first sensitization. The longer time period 
between the first two sensitizations might enable the induction of IgE before the 
second sensitization. Thus the tropomyosin specific IgE level continued to boost up 
during the sensitization process. The re-exposure of the tropomyosin at higher 
concentration during challenge activated the allergic response and initiated the IgE 
production and thus the allergic reactions, for example, swelling of snout and 
scratching. 
Since the tropomyosin specific IgE might not have been built up at the second 
sensitization in the first protocol, the tropomyosin specific IgE remained at low level 
after the second sensitization. When the third sensitization was given, the IgE had 
been produced and the IgE level started to boost up by further sensitization. Then the 
effect of the third sensitization in the first protocol was similar to the second 
sensitization in the second protocol. Fig. 3.8 shows that the IgE level of the first 
protocol was comparable to the IgE level of previous sensitization in the second 
protocol. Similarly, the IgE level at the fourth sensitization of the first protocol was 
comparable to the third sensitization of the second protocol, and the IgE level after 
challenge of the first protocol was comparable to the fourth sensitization of the second 
protocol. 
As mentioned in the introduction, the use of BALB/c mice as animal model for 
studying shrimp allergy was firstly developed by Tang (2004). He showed that the 
tropomyosin-specific IgE was significantly higher in mice fed with 0.1 mg 
tropomyosin with adjuvant after challenge and maintained at high level one week 
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after challenge. Thus the first feeding protocol in the current study was same as the 
sensitization duration and protein amount used in Tang's study. Despite his result 
found that the tropomyosin-specific IgE was significantly higher after the fourth 
sensitization, there was no statistical difference in IgE level between mice fed with 
tropomyosin and PBS using the same protocol in the present study (Fig, 3.6). 
Swelling of the snout, rubbing around the snout and scratching the whole body 
including the tail were observed in mice fed with 0.1 mg tropomyosin by Tang. 
However, no anaphylactic symptom was observed in mice fed with 0.1 mg 
tropomyosin using the first feeding protocol. Since the result of the first feeding 
protocol was not ideal, the second feeding protocol was designed. The 
tropomyosin-specific IgE level in mice fed with 0.1 mg tropomyosin using the second 
feeding protocol was significantly higher after the third and fourth sensitization and 
challenge (Fig. 3.7). Anaphylactic symptoms including swelling of snout and 
scratching around the body were observed in this group of mice. These results were 
similar to those found by Tang. Because the use of the second feeding protocol 
showed better results in allergy sensitization, mice fed with the secondary protocol 
were used for the epitope mapping experiment in chapter 4. The differences arise in 
the same protocol between Tang's and the current study might be due to many factors. 
Although the same strain of mice should have similar immune response to antigens, 
environmental and genetic factors might affect the immune system from generation to 
generation. Tang's experiment was conducted at School of Medicine, National Taiwan 
University Hospital, National Taiwan University. The variation of immune response 
of mice used in Taiwan and Hong Kong could explain why different 
tropomyosin-specific IgE levels were obtained although the experimental setups were 
the same. 
65 
Generating food allergy models that reflect human food hypersensitivity is 
difficult because of the strong innate tendency of oral tolerance developed in mice. 
Cholera toxin, a potent mucosal adjuvant for secretary IgA antibody responses to 
protein antigens in some strains of mice, was used in order to bypass the state of 
tolerance (Elson and Balding 1987, Wilson et al 1989). It has also been shown to 
stimulate production of IgE and IgGl antibodies, as well as Th2 cells and IL-4 
(Marinaro et al. 1995, Saloga et al 1993). However, oral tolerance in mice was also 
influenced by age (Hanson 1981，Strobel and Ferguson 1984, Strobel 1996), strain 
(Ito et al 1997，Kiyono et al 1982) and the nature and dose of the sensitized protein 
(Ito et al. 1997, Lament et al 1989, Mowat 1987，Poulsen et al 1987). Therefore, 
more studies are needed to optimize all parameters for developing a reliable shrimp 
allergy animal model. A reliable animal model can be used for immunotherapy 
development to treat shrimp allergy and seafood allergy. 
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Chapter 4 
Identification of T cell eptiopes 
4.1 Introduction 
The development of an IgE mediated immune response requires a series of direct 
and indirect cellular interactions involving APCs，T and B cells. The entire immune 
mechanism is initiated by the APCs which process the allergen and present small 
peptide fragment containing T cell epitopes in conjunction with M H C class II 
molecules on the cell surface. The peptide-MHC complex will be recognized by the 
corresponding T cell receptor on the CD4+ Th cells. The activation of the CD4+ Th 
cells triggers a series of immune reactions which have been described in chapter 2. 
Thus the detailed analysis of the T cell response against allergens, including the 
identification of relevant T cell epitopes and cytokine synthesis, is an important 
contribution to a comprehensive characterization of allergenic proteins. This 
knowledge can improve the understanding of the pathophysiology of allergic diseases 
and the development of immunotherapy. 
There are various developments of immunotherapeutic strategies designed to 
alter the immune system's response to food allergens. Specific immunotherapy (SIT) 
as discussed in section 2.5 perhaps is the only effective therapeutic intervention of 
allergy. Over time, the individual becomes less reactive to the allergen. Peptide 
immunotherapy reduces the allergen to its component CD4+ T cell epitopes. Because 
these peptides are too short to crosslink IgE, higher molar doses of T cell activating 
peptides can be delivered. A number of animal models of peptide therapy in allergic 
disease have been developed. These studies show that SIT is effective in animal 
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models, and is thus potentially promising in human immunotherapy. It should be 
noted that knowledge on T cell epitopes in the allergen of interest is necessary so that 
T cell epitopes can be retained in the design of peptides. 
In this chapter, the T cell epitopes of Met e 1 will be identified by the 
proliferation assay. T cell epitopes are short, linear peptides which are recognized and 
bound by the T cell receptor. Briefly, splenocytes from sensitized BALB/c mice are 
stimulated with overlapping synthetic peptides representing the complete amino acid 
sequence of Met e 1. Synthetic peptides are divided into six synthetic peptides pools 
and each contains three different synthetic peptides. Mice splenocytes are sensitized 
by each synthetic peptides pool and also single synthetic peptide. Peptides that induce 
splenocyte proliferation in T cell culture represent the presence of the T cell epitopes. 
The characterization of the T cell epitopes is essential to allergenic response analysis 
as this is the first step to trigger the immune mechanism. 
4.2 Materials and Methods 
4.2.1 Soluble epitope peptide synthesis 
Seventeen 20-residue and one 19-residue peptides with five-residue 
overlapped were synthesized by Fmoc protocols on an automated peptide synthesizer. 
These synthetic peptides encoded the full length of Met e I. They were purified to 
>95% by high performance liquid chromatography (HPLC). The amino acid sequence 
and the corresponding regions of the 18 peptides are shown in Fig. 4.1. 
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4.2.2 Isolation of spleen cells from mice 
Mice which showed high tropomyosin IgE level and hypersensitivity 
symptoms including swelling of snout and scratching were scarified by spinal 
dislocation after blood collection. It was performed on day 34, the day after challenge. 
The details of the mice sensitization process had described in section 3.2.9. Spleens 
were removed from the mice with sterile surgical scissors and forceps. Isolated 
spleens were put in PBS supplemented with 0.2% BSA immediately and stored in ice. 
Spleen cells were isolated by grinding with the piston of 5 ml syringe in 10 ml PBS 
supplemented with 0.2% BSA. The mixture was allowed to stand for 5 minutes in ice 
for settling of the debris. Supernatant was transferred to clean falcon tubes and 
centrifuged at 1500 x g for 10 minutes at 4°C. The pellet was resuspended and 
incubated with 1 ml A C K solution (8.29 g NH4CI, 1.0 g KHCO3 and 37.2 mg 
Na2-EDTA in 1 L dHzO at pH 7.2, 0.22 [xm filtered) for 1 minute to lyse the red blood 
cells in the culture. 9 ml Hanks' Balanced Salt Solution (HBSS) (Sigma, Cat. No. 
H-2387) were added and the mixture was centrifuged at 1500 x g for 10 minutes at 
4°C. Supernatant was discarded and the pellet was resuspended in 10 ml HBSS and 
centrifuged at 1500 x g for 7 minutes at 4°C. This procedure for washing cells was 
repeated twice. The pellet was resuspended in 1 ml complete cell culture medium, 
(RPMI-1640 supplemented with 10% fetal calf serum, 1% penicillin/ streptomycin 
and 1% glutamine) for cell count. 10 cell suspension was mixed with 10 Trypan 
blue. 10 |j,l of the mixture was added into hemocytometer for counting the number of 
viable cells. Spleen cells from several mice were pooled together for the proliferation 
assay and cytokine assay. 
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4.2.3 T cell proliferation assay 
5x 10^  spleen cells per well were cultured in quadruplicate in 96-well 
U-bottom plates with 10 |ag/ml of each tested synthetic peptide or synthetic peptides 
pool. Each synthetic peptide pool contained three different synthetic peptides at 10 
|ig/ml each. Cells stimulated with 10 |ig/ml phytohemagglutinin (PHA) and 10 |ag/ml 
recombinant tropomyosin were used as positive. The non-specific protein ovalbumin 
(OVA) was used as negative control. The culture plates were incubated at 37°C in 5% 
CO2 for 48 hours. 0.5 |aCi tritiated thymidine (Amersham Bioscience, Cat No. TRA61) 
per well was added into the culture and incubated for another 15 hours. Then the cells 
were harvested and the tritiated thymidine incorporation was measured by a (3-
scintillation counter in counts per minute (cpm). Proliferation data were expressed as 
stimulation index, which was the ratio of incorporated radioactivity in the presence 
and absence of testing peptides (i.e. spenocytes culture in culture medium only). A 
stimulation index greater than three was considered as significant proliferation of 
spleen cells. 
The stimulation of spleen cells with individual synthetic peptide was 
repeated four times. In each replicate, spleen cells from mice in single batch were 
used. Proliferation assays were performed twice with synthetic peptides pools. In the 
first time, 18 synthetic peptides were divided into six groups, they were peptide 1-3, 
4-6, 7-9，10-12, 13-15 and 16-18. Different synthetic peptides combination was used 
in the second time. In the second trial, the synthetic peptides were divided into five 






































4.3.1 Splenocyte proliferation to synthetic peptide 
The results varied among the four replicates but a trend was shown. By 
considering a S.I. value >3 as positive, three T cell epitopes were identified (Fig. 4.2 
A). They were the peptide 4, 10 and 15, representing residues 53-72，143-162 and 
218-237 in recombinant tropomyosin respectively. These peptides had higher S.I. 
value than the other peptides in the other three replicates (Fig. 4.2 B-D) although their 
S.I. value in these replicates were smaller than three. Peptide 10 showed S.I. values 
>2 in the second and third replicates (Fig. 4.2 B，C) and >1.5 in the fourth replicate 
(Fig. 4.2 D). Peptide 15 showed S.I. value >2 in the second replicate (Fig. 4.2 B) and 
>1.5 in the third and fourth replicates (Fig. 4.2. C, D). If we considered S.I. value >2 
as positive, five more T cell epitopes were identified (Fig. 4.2 A). They were peptides 
2，3, 8，14 and 17，representing residues 23-42, 38-57, 113-132, 203-222 and 248-267 
in recombinant tropomyosin respectively. But, these five peptides had similar S.I. 
values to other peptides in the other three cell proliferation replicates (Fig. 4.2 B-D). 
4.3.2 Splenocyte proliferation to synthetic peptides pool 
The proliferation assay with synthetic peptides pools were done twice. In 
the first set of experiment (Fig. 4.3A), three out of six synthetic peptide pools showed 
relatively higher S.I. values than the other peptide pools. These three synthetic 
peptides pools which contained peptides 4-6, 10-12 and 13-15 respectively showed 
S.I. values >2 in the experiment. 
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Based on the preliminary data, the second set of experiment was performed 
with different combination of synthetic peptides pools (Fig. 4.3B). In this proliferation 
assay, three out of five synthetic peptide pools showed relatively higher S.I. values 
than the other peptide pools. These three synthetic peptides pools which contained 
peptides 2-4, 8-10 and 15-17 respectively showed S.I. values >2.5 in the experiment 
while the rest showed S.I. values <1.5. 
In the positive control where PHA was used, S.I. value was higher than 100 
as PHA was a cell stimulator. In contrast, S.I. value was 1 when OVA was used 
because OVA had no stimulation effect to cells. The addition of OVA had the same 
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Fig. 4.2 Splenocytes stimulation by Met e 1 peptides. The cell proliferation assay 
was repeated four times (A-D) and stimulation index of each peptide was 
determined. Stimulation index was calculated as the ratio of incorporated 
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Fig. 4.3 Splenocyte stimulation by Met e 1 peptide pool. Each peptide pool was 
mixed with 3 different peptides at 10 |xg/ml each. Stimulation index of each 
pool was determined and calculated as a ratio of incorporated radioactivity 
in the presence and absence of testing peptides. Note the high stimulation 
index for synthetic pools containing synthetic peptides 4，10 or 15. 
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4.4 Discussion 
Seafood allergy is a serve, untreatable condition. At present avoidance is the only 
treatment for seafood allergy but avoidance can be difficult to achieve. Since allergen 
immunotherapy should be curative, the identification and immunologic 
characterization of seafood allergens is an important step towards the development of 
rational treatments for this disorder. Specific immunotherapy (SIT) which has been 
detailed discussed in section 2.5 is found to be an effective therapeutic intervention 
for allergy. The identification of T cell epitopes is critical to the development of this 
therapy. In this chapter, T cell epitopes of tropomyosin using sensitized BALB/c mice 
were identified. 
The results showed that of the 18 synthetic peptides of tropomyosin, three of 
them (peptides 4，10 and 15) showed higher stimulation index (S.I) values than the 
others. Stimulation index value is a reflection of the size of T cell population specific 
for the antigen or peptide. Therefore the peptides with high stimulation index likely 
represent the dominant epitopes. In the present study, splenocyte culture was used 
instead of T cell line (TCL) or T cell clone (TCC). For splenocyte culture, synthetic 
peptides usually induce weaker proliferation than TCL or TCC, an S.I. higher than 
three was defined as a cut-off for positive response. For results showing S.I. lower 
than two, it was considered as negative. Although the four replicates showed 
fluctuation, we could observe a similar pattern from them. The synthetic peptides 4 
(residues 53-72), 10 (residues 143-162) and 15 (residues 218-237) always showed 
higher S.I. values than the others peptides even though the S.I. values are lower than 
three in some replicates (Fig. 4.2 A-D). Tang (2004) showed that S.I. value for 
splenocyte proliferation sensitized with recombinant tropomyosin was greater than 
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three. Thus, three was used as positive cut-off in this experiment. Recombinant 
tropomyosin was used as positive control in this experiment and it showed S.I. value 
of higher than ten. The S.L values which were greater than three of the synthetic 
peptides 4, 10 and 15 indicated that these peptides were potential T cell epitopic 
regions. 
In addition to individual synthetic peptides, splenocyte proliferations with pooled 
synthetic peptides which contained three different synthetic peptides in each pool 
were performed. Two different sets of synthetic peptide pool were used (Fig. 4.3). In 
the first set of experiment (Fig. 4.3A), synthetic peptide pools contained synthetic 
peptides 4-6 (residues 53-102), 10-12 (residues 143-192) and 13-15 (residues 188-237) 
showed slightly higher S.I. values than the other three pools. In the second set of 
experiment (Fig. 4.3B), synthetic peptide pools which contained synthetic peptides 
2-4 (residues 23-72), 8-10 (residues 113-162) or 15-17 (residues 218-267) showed 
relatively higher S.L values than the other pools. Their S.L values were higher than 
those pooled synthetic peptides in the first set (Fig. 4.3A). The proliferation assay 
results of pooled synthetic peptides were consistent with the cell proliferation assay of 
individual synthetic peptides. First of all, the six pools of synthetic peptides stated 
before contained the synthetic peptides 4，10 or 15. Secondly, these six synthetic 
peptide pools also contained five single synthetic peptides (peptides 2，3，8，14 and 17) 
which had S.I. values greater than two in the proliferation assay with individual 
synthetic peptide. It further supports that synthetic peptides 4，10 and 15 are putative 
dominant T cell epitopic regions and synthetic peptides 2, 3, 8, 14 and 17 are putative 
minor T cell epitopic regions. The difference between the two proliferation assays 
with pooled synthetic peptides was the combination of peptides used. It showed that 
when only 1 peptide changed, the degree of splenocyte proliferation could be 
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increased significantly. For example, S.I. value of the synthetic peptide pool which 
contained peptides 1，2 and 3 was less than 1.5. Once peptide 1 was replaced with 
peptide 4，the S.I. value increased close to 4. If the synthetic peptide 7 in the pooled 
synthetic peptide 7-9 was replaced with peptide 10，or the synthetic peptide 18 in the 
pooled synthetic peptide 16-18 was replaced with peptide 15，similar results were 
observed that the S.L values increased from less than 2 to close to 3. The increase of 
S.I. value may be due to the presence of the T cell epitopes. When the splenocytes 
were stimulated by more than one synthetic peptide, the proliferation rate would be 
increased or decreased by the other peptide present. Thus substitutions for another 
synthetic peptide lead to different degrees of cell proliferation. 
In the second pooled synthetic peptide proliferation assay (Fig. 4.3B), peptides 1 
and 14 were not used. Since peptide 1 consistently showed low S.I. value in 
individual synthetic peptide proliferation assay, it was assumed that peptide 1 was not 
a potential T cell epitope. Moreover, peptide pool with synthetic peptides 1-3 were 
performed and showed the lowest S.L value. A potential T cell epitope identified by 
Subba Rao et al (1998) was covered by peptides 15-18 in the present study (Fig. 4.4). 
Thus cell proliferation was tested with these four peptides. Synthetic peptide pools 
16-18 (Fig. 4.3A) and 15-17 (Fig. 4.3B) were used for cell proliferation. Peptide 14 
was not used in the second proliferation assay because synthetic peptide pools 11-13 
and 15-17 were used. To improve the experiment, synthetic peptide 14 should be 
tested by pooling synthetic peptides into 14-16 and stimulating cell proliferation. 
Subba Rao et al. (1998) identified six predicted T cell epitopic regions of Met e 1 
on the basis of a computer algorithm developed by Berzofsky and synthesized the 
peptides with a solid-phase synthetizer. They further tested the ability to induce in 
vitro proliferation of splenocytes isolated from mice immunized with native Met elm 
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a recall assay. They found that between the six peptides, peptide 6 spanning the region 
261-281 was able to induce proliferation comparable to the native allergen, indicating 
that this peptide was a putative T cell epitope. Subba Rao et al also demonstrated the 
capacity of this peptide to down regulating an established allergen-specific antibody 
response in vivo in BALB/c mice. Their study showed that both tropomyosin-specific 
IgG and IgE level reduced significantly after administration of the peptide and the 
sensitized mice were able to maintain the low titers of antibodies level beyond 30 
days. In the present study, part of the peptide 17 spanning the region 248-267 
overlapps with the putative T cell epitope identified by Subba Rao et al (Fig. 4.4). T 
cell epitope is defined as the smallest sequence of amino acids that can be recognized 
by the T helper cell. It was possible that the T cell epitope located at the region 
261-267 and as a result both the peptide 17 in the present study and peptide 6 in 
Subba Rao et aVs experiment showed splenocyte proliferation capacity. However, 
peptide 17 did not show the highest level of splenocyte proliferation of the 18 










































































































































































































































































































































































































































































































Although Subba Rao et al (1998) identified six predictive T cell epitopes, only 
one (peptide 6) was suggested to be the T cell epitope at last. In the present study, 
some peptides which showed higher S.L values in the proliferation assays with 
individual peptides were identified as predictive T cell epitopes by Subba Rao et al 
Pooled synthetic peptide 2-4 contained synthetic peptides 2，3 and 4. These three 
synthetic peptides spanning the residues 23-72 entirely overlaps with peptide 1 
spanning the residues 26-66 used in Subba Rao's study (Fig. 4.4). The results of 
splenocyte proliferation with the pooled synthetic peptide 2-4 showed the highest S.L 
value of the synthetic peptide pools. In other words, the residues 23-72 can stimulate 
the splenocytes to proliferate. Another peptide of the present study, peptide 10， 
overlaps with peptide 4 of Subba Rao's study (Fig. 4.4). Although peptide 4 did not 
stimulate splenocyte proliferation, peptide 10 showed relatively higher S.I. value in 
the splenocyte proliferation assay (Fig. 4.2A-D). Peptide 8 which showed S.L value 
greater than 2 in the present study was totally overlapped with peptide 3 in Subba 
Rao's study (Fig. 4.4). But Subba Rao et al. did not consider peptide 3 as T cell 
epitope since they found that this peptide could not induce splenocyte proliferation. 
Since the mapping of the synthetic peptides was not the same in the two experiments, 
results would be affected by the amino acids composition of the peptides. So 
perhaps peptides 2, 3，4，8，and 10 were potential T cell epitopes but the effect of 
splenocyte proliferation was masked by the linkage with other amino acids in the 
same peptides. For further investigation, it was suggested to synthesize shorter 
peptides and increase the number of amino acid residues overlapping. This should 
give a clearer picture about the location of the short epitopes. 
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Fig. 4.5 Amino acid sequence comparison of tropomyosin from Metapeaneus ensis 
(Shrimp), Homarus americanus (American lobster), Panulirus stimpsoni 
(Spiny lobster), Charybdis feriatus (Crab), Perna viridis (Mussel), Haliotis 
Panulirus (Abalone), Chlamys nobilis (Scallop), Salmo salar (Salmon), 
Xenopus laevis (Frog) and Rattus norvegicus (Rat). All sequences are 
available from GenBank. Note that the potential T cell epitopes indicated in 
the boxes are highly conserved in crustaceans. 
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Fig. 4.5 shows the amino acid alignment of tropomyosin of different 
invertebrate and vertebrate species. It was identified that crustacean (shrimp, 
American lobster, spiny lobster and crab) tropomyosin isoforms were highly 
conserved with amino acid identity close to or greater than 90%. It is also shown that 
amino acid sequences of tropomyosin of mollusks were conserved with identity >68%. 
A higher degree of identity was revealed among shellfish. When tropomyosin 
sequences of vertebrates (salmon, frog and rat) are included in the alignment, it is 
noted that amino acid sequences of vertebrate tropomyosin were less conserved. The 
sequence divergence explains why there is a lack of allergenic cross-reactivity 
between shellfish and vertebrate tropomyosins. The presence of common IgE-binding 
epitopes among shellfish but not in vertebrates is apparently due to the different 
amino residues in the epitopic region. For example, one of the major epitopic regions, 
amino residues 249-281, was more conserved in shellfish than vertebrates. The 
difference in amino acid sequence leads to the lack of cross-reactivity in allergenicity 
and thus vertebrate tropomyosin was not allergenic (Chu et al 2000). 
The three potential T cell epitopes (synthetic peptides 4, 10 and 15) are indicated 
in Fig. 4.5. These epitopes are highly conserved in crustacean including shrimp, 
American lobster, spiny lobster and crab. The amino acid sequences of synthetic 
peptide 4 of the crustaceans are conserved with identity >90%. For synthetic peptides 
10 and 15，the amino acid sequences are identical. The highly conversed epitopic 
regions in crustacean suggest that T cell epitopes are unique in crustaceans. 
As mentioned in the previous paragraph, both of the synthetic peptide 17 of the 
present study and peptide 6 in Subba Rao's study showed splenocyte proliferation 
capacity. The overlapped region of these two peptides constitute the amino residues 
261-267 (KEKYKSI). This region was highlighted by a bold box in Fig. 4.5. It was 
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identified that this region was nearly 100% identical in shellfish but quite different 
from vertebrates. Thus the exposure of vertebrate tropomyosin would not stimulate 
allergic response as shellfish allergen in allergic patient since the T cell receptor could 
not be stimulated. 
Some studies suggested that SIT was the only effective therapeutic intervention 
for allergy. To improve the efficacy and safety of SIT, IgE binding epitopes of the 
intact recombinant allergens should be modified to reduce IgE binding, but with all 
potential T cell epitopes intact (Harding 2003). If the IgE binding epitopes were T cell 
epitopes, then we should decide whether this epitopic region should be modified. 
Since the eight IgE binding epitope region of Pen a 1 found by Ayuso et al (2002a) 
are conserved in Penaeus aztecus and Metapenaeus ensis, it is possible to compare 
these epitopes to the putative T cell epitopes identified. Within the eight IgE binding 
epitope region, two regions overlap with the putative T cell epitopes: epitope 3b 
spanning the region 144-151 and epitope 1 spanning the region 43-55 overlap with the 
synthetic peptide 10 and 3 respectively. Subba Rao et al (2002) also identified two 
IgE binding epitope regions of Met e 1. The first IgE binding epitope region (residues 
47-53) is same as epitope 1 identified by Ayuso et al and the second one (residue 
150-158) is a new epitope discovered. The comparison of these two IgE binding 
epitope regions and the putative T cell epitopes showed that the IgE binding epitope 
regions overlap with the synthetic peptide 3 and 10 of the present study respectively. 
Thus these two epitopic regions, residues 38-57 and 143-162, should remain intact in 
order to maintain the T cell epitopes when producing modified recombinant 
tropomyosin for SIT. 
From the results, when splenocytes were stimulated with recombinant protein, 
the S.I. value of splenocyte proliferation was higher than stimulated with 20-mer 
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overlapping peptides. This observation was in line with the study of human T cell 
epitopes in Japanese cypress pollen allergen, Cha o 1 (Sone et al 2005). It is because 
T cells are reactive to several T cell epitopes derived from native recombinant allergen 
while T cells stimulated with synthetic peptides responded to single T cell epitope 
situated in individual peptide. As a result, lower S.I. value of splenocyte proliferation 
was considered to be positive response when splenocytes were stimulated with 
synthetic peptides. 
In the present study, splenocytes were used as a source for T cells. Splenocytes 
can be any one of the different white blood cell types as long as these cells are 
situated in the spleen or purified from spleen tissue. The proportion of 
allergen-specific T cells is rather low in the splenocyte culture. Besides，the 
allergen-specific T cells culture contains T cells with different epitope specificities. As 
a result, the number of epitope-specific T cells in each culture is limited after several 
dilutions and the stimulation efficiency of the synthetic peptides is restricted. This 
may be a possible reason of the fluctuation in S.I. values in different proliferation 
assay replicates and the relatively low S.I. values when using synthetic peptides 
containing the potential T cell epitope in some replicates. In this case, some of the 
minor epitopes may be missed too. It is because T cells in the cell culture, are specific 
to different epitopes. If synthetic peptides containing minor epitopes are added, the 
possibility of binding to the specific T cells is low. Moreover, even the T cell epitopes 
are recognized, the efficacy of stimulation may not be strong enough to give a high 
S.L value in the proliferation assay. Then these minor epitopes are not detected. 
Recently, T cell line (TCL) or T cell clone (TCC) are utilized for investigating the T 
cell response, including T cells epitopes and cytokine profiles characterization in 
several studies on allergenicity (Bohle et al, 2005b, Immonen et al 2005, Sone et al, 
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2005). By adding IL-2 and allergen into the cell culture, allergen-specific T cells 
proliferated preferentially since T cells express IL-2 receptors. The resulting culture 
which contains a mixture of T cells enriched for allergen-specific T cells with 
different specificities is called TCL (Bohle 2006). Allergen-specific TCLs are useful 
for gaining an overview on the different T cell activating regions within a particular 
allergen. These cultures contained T cell subpopulations with different specificities 
and therefore, reveal a broad spectrum of epitopes recognized. Monoclonal cultures, 
TCCs，can be generated from TCLs by limiting dilution. TCCs are specific to single 
epitope and epitope mappings can be performed using the monoclonal TCCs. 
Allergen-specific T cell clones were derived from house dust mite-allergic and 
pollen-allergic individuals in the 1980s and have been used to address a number of 
questions which could not be addressed by polyclonal techniques. Important 
information are gained about the T cell epitopes of common airborne allergens in 
1987 (O'Hehir et al. 1987). Compared to TCLs, TCCs are more useful for 
characterizing the expression of surface markers defining their subset and homing 
markers. Furthermore, the expression of T cell receptor gene families and the cytokine 
response to stimulation with an allergen or a peptide containing a particular epitope 
can be analyzed. To improve the experiment, TCLs can be used in the proliferation 
assay for identifying eptiopes recognized by a single individual. Then 
immunodominant T cell epitopes can be characterized by comparing the epitope 
recognition patterns of a large number of individuals. 
Although T cell epitopes cannot be clearly identified through the present 
experiment, we have gained knowledge about the potential location of the epitopes. 
Three dominant epitopes which spread along the entire allergen are revealed. In the 
future, the experiment can be modified by performing proliferation assay for each 
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mouse separately or using TCLs for the assay. It is believed that the epitopic regions 




The present study showed that tropomyosin-specific IgE was induced in mouse 
model by feeding tropomyosin orally for a period of time. It is found that after 
challenge, tropomyosin-specific IgE was induced actively when the duration between 
the first and second sensitization was longer. Moreover, hypersensitivity responses 
were provoked in the mouse model. The different result obtained from the two 
feeding protocols may be due to the tolerance of mice or the delay of T cell 
stimulation after the first sensitization. 
T cell epitopes were identified using the tropomyosin allergic mouse model. 
Splenocytes were extracted from the sensitized mice and stimulated with different 
synthetic peptides. T cell epitopes were identified by measuring the proliferation rate 
of splenocytes. 18 peptides spanning the full length of the tropomyosin were 
synthesized and added into the cell cultures individually or in groups. The results 
showed that splenocytes were proliferated actively when the synthetic peptide 4 
(residues 53-72), 10 (residues 143-162) and 15 (residues 218-237) were added 
individually. It was suggested that these peptides are potential T cell epitopes. 
Splenocytes proliferation was also observed when synthetic peptides groups which 
contained peptides 4, 10 or 15 were added. This further supports that these three 
regions are the potential T cell epitopes. Other than the three T cell epitopes 
mentioned above, five more synthetic peptides were identified as minor T cell 
epitopes. The synthetic peptides 2 (residues 23-42), 3 (residues 38-57)，8 (residues 
113-132), 14 (residues 203-222) and 17 (residues 248-267) showed higher rate of 
splenocyte proliferation than the rest when added into the cell culture. Moreover, 
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when these peptides were added with synthetic peptides 4，10 and 15 in groups, 
splenocytes were induced to proliferate more actively. Because these 5 synthetic 
peptides showed lower inductivity to splenocytes proliferation, they are considered to 
be minor T cell epitopes while synthetic peptides 4，10 and 15 are major T cell 
epitope. 
Similar study was performed by Subba Rao et al (1998). It was found that some 
of the major and minor T cell epitopes proposed in the present study were identified 
as predictive T cell epitopes by Subba Rao et al. The pooled synthetic peptide 2-4 
spanning the residues 23-72 entirely overlaps with peptide 1 (residues 26-66) used in 
Subba Rao's study. The results of splenocyte proliferation with this synthetic peptide 
pool showed the highest S.L value within all synthetic peptide pools. Peptides 8 and 
10 which showed relatively higher S.L value in the splenocyte proliferation assay in 
the present study overlaps with peptides 3 and 4 in Subba Rao's study. But these two 
peptides were not considered to be T cell epitopes by Subba Rao et al since they 
could not induce splenocyte proliferation in that study. Although Subba Rao et al. 
identified six predictive T cell epitopes, only one (peptide 6) was suggested to be the 
T cell epitope at last. Peptide 6 partly overlaps with peptide 17 in the present study at 
residues 261-267 (KEKYKSI). Since peptide 6 and peptide 17 showed splenocyte 
proliferation in Subba Rao's and present study respectively, it is possible that a T cell 
epitope locates at the residues 261-267. From the alignment of tropomyosin sequence, 
it is noted that this short region is 100% identical in shellfish but different from 
vertebrates. It is suggested that this T cell epitope is unique in shellfish. 
The alignment of tropomyosin amino acid sequence of invertebrate and 
vertebrate species shows that tropomyosin was highly conserved in shellfish. The lack 
of allergenicity of vertebrate tropomyosin was due to the different amino acid 
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sequence of vertebrate tropomyosins from invertebrate tropomyosins. Since the amino 
acid sequences of the putative B cell epitopes and T cell epitopes in invertebrates are 
distinct from those in vertebrates, vertebrate tropomyosin is not allergenic to 
tropomyosin allergic patients. 
The present study successfully develops a tropomyosin allergic mouse model and 
identifies 3 major and 5 minor T cell epitopes. It is believe that the mouse model can 
be used for future studies on seafood allergy and the identification of T cell epitopes 
provides information for developing novel therapies to seafood allergy. 
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